<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        38-355-06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2006
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MITOXANTRON EBEWE 2MG-1ML SOL. FOR INFU
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MITOXANTRONE HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        396.70
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value=" Fareva Unterach GmbH " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                             Fareva Unterach GmbH 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            EBEWE PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01DB07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Mitoxantron &ldquo;EBEWE&rdquo; contains the active substance mitoxantrone. Mitoxantron &ldquo;EBEWE&rdquo; belongs to&nbsp; the group of medicines known as antineoplastic or anti-cancer medicines. It also belongs to the subgroup of anti-cancer medicines called anthracyclines. Mitoxantron &ldquo;EBEWE&rdquo; prevents cancer cells from growing, as a result of which they eventually die. The medicine also suppresses the immune system and is used because of this effect to treat a specific form of multiple sclerosis when there are no alternative treatment options.</p><p>Mitoxantron &ldquo;EBEWE&rdquo; is used in the treatment of:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; advanced stage (metastatic form) of breast cancer;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a form of lymph node cancer (non-Hodgkin&rsquo;s lymphoma);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a cancer of the blood in which the bone marrow (the spongy tissue inside the large bones) makes too many white blood cells (acute myeloid leukaemia);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a cancer of the white blood cells (chronic myeloid leukaemia) at a stage where it is difficult to control the number of white blood cells (blast crisis). Mitoxantron &ldquo;EBEWE&rdquo; is used in combination with other medicinal products in this indication;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain caused by prostate cancer at an advanced stage of prostate cancer in combination with corticosteroids;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; highly active relapsing multiple sclerosis associated with rapidly evolving disability where no alternative therapeutic options exist (see sections 2 and 3).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;Do not use Mitoxantron &ldquo;EBEWE&rdquo;</strong></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to mitoxantrone or any of the other ingredients of this medicine (listed in section 6);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to sulphite;</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a form of asthma (bronchial asthma) with sulphite allergy;</p><p>-</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are breast-feeding (see section &ldquo;Pregnancy and breast-feeding&rdquo;)</p><p><u>For use as treatment of multiple sclerosis</u>:</p><p>-&nbsp; if you are pregnant.</p><p><strong>Warnings and precautions</strong></p><p>Mitoxantron &ldquo;EBEWE&rdquo; should be administered under the supervision of a doctor experienced in the use of cancer medicines that are toxic to your cells (cytotoxic chemotherapy agents).</p><p>Mitoxantron &ldquo;EBEWE&rdquo; should be given by slow and freely flowing infusion into the vein. Mitoxantron &ldquo;EBEWE&rdquo; must not be administered under the skin (subcutaneous), in a muscle (intramuscular), or into the artery (intra-arterial). Severe local tissue damage may occur if Mitoxantron &ldquo;EBEWE&rdquo; leaks in surrounding tissue (extravasation) during administration.</p><p>Mitoxantron &ldquo;EBEWE&rdquo; must also not be injected into the space under the brain or spinal cord (intrathecal injection) as this can result in severe injury with permanent impairment.</p><p><strong>Talk to your doctor or, pharmacist or nurse before using Mitoxantron &ldquo;EBEWE&rdquo;:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have liver problems;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have kidney problems;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have used Mitoxantron &ldquo;EBEWE&rdquo; before;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if your heart is not working well;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you had prior radiotherapy of the chest;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you already use other medicines that affect your heart;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you had previous therapies with anthracyclines or anthracenediones, such as daunorubicin or doxorubicin;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if your bone marrow is not working well (is depressed) or if you are in generally poor health;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have an infection. This infection should be treated before taking Mitoxantron &ldquo;EBEWE&rdquo;;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you plan a vaccination or immunisation during treatment. Vaccinations and immunisations may not work during treatment with Mitoxantron &ldquo;EBEWE&rdquo; and for 3 months after the end of treatment;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are pregnant or if you and your partner are trying to become pregnant;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are breast-feeding. You should stop breast-feeding before taking Mitoxantron &ldquo;EBEWE&rdquo;.</p><p>&nbsp;</p><p>&nbsp;</p><p>Tell your doctor or pharmacist or nurse immediately if you get any of the following signs or symptoms during treatment with Mitoxantron &ldquo;EBEWE&rdquo;:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever, infections, unexplained bleeding or bruising, weakness and easy fatigability;</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breathlessness (including breathlessness at night), cough, fluid retention (swelling) in the ankles or legs , heart fluttering (irregular heart beat). This may occur either during or months to years after therapy with Mitoxantron &ldquo;EBEWE&rdquo;.</p><p>&nbsp;</p><p>Your doctor may need to adjust your treatment or stop Mitoxantron &ldquo;EBEWE&rdquo; temporarily or permanently.</p><p><strong>Blood tests prior and during treatment with Mitoxantron &ldquo;EBEWE&rdquo;</strong></p><p>Mitoxantron &ldquo;EBEWE&rdquo; may affect your blood cell counts. Before you start Mitoxantron &ldquo;EBEWE&rdquo; and during treatment, your doctor will do a blood test to count the number of your blood cells. Your doctor will carry out blood tests more often, in which he will in particular monitor the number of white blood cells (neutrophilic leucocytes) in the blood:</p><p>&bull;&nbsp; <!--[if gte vml 1]><v:shapetype id="_x0000_t202" coordsize="21600,21600"
 o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_3" o:spid="_x0000_s1027"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:125.4pt;margin-top:12.5pt;width:2.3pt;height:5.05pt;z-index:-19936;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]-->if you have a low count of a specific type of white blood cells (neutrophils) (less than 1,500 cells/mm );</p><p>&bull;&nbsp;<span style="text-align:unset">if you use Mitoxantron &ldquo;EBEWE&rdquo; in high doses (&gt;14 mg/m per day x 3 days).</span></p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Heart function tests prior and during treatment with Mitoxantron &ldquo;EBEWE&rdquo;</strong></p><p>Mitoxantron &ldquo;EBEWE&rdquo; may damage your heart and cause a deterioration of your heart function or in more severe cases heart failure. You are more prone to these side effects if you take higher doses of Mitoxantron &ldquo;EBEWE&rdquo; or:</p><p>&bull;&nbsp; if your heart is not working well;</p><p>&bull;&nbsp; if you had prior treatment of the chest with radiation;</p><p>&bull;&nbsp; if you already use other medicines that affect your heart;</p><p>&bull;&nbsp; if you had previous therapies with anthracyclines or anthracenediones, such as daunorubicin or doxorubicin.</p><p>&nbsp;</p><p>Your doctor will do heart function tests before you start Mitoxantron &ldquo;EBEWE&rdquo; and at regular intervals during therapy. If you receive Mitoxantron &ldquo;EBEWE&rdquo; to treat multiple sclerosis your doctor will test your heart function before the start of therapy, prior to each subsequent dose and yearly for up to 5 years after the end of therapy.</p><p><strong>Acute myeloid leukemia (AML) and Myelodysplastic syndrome</strong></p><p>A group of anticancer medicines (topoisomerase II inhibitors), including Mitoxantron &ldquo;EBEWE&rdquo;, may cause the following diseases when used alone but especially in combination with other chemotherapy and/or radiotherapy:</p><p>&bull;&nbsp; cancer of white blood cells (acute myeloid leukaemia, AML)</p><p>&bull;&nbsp; a bone marrow disorder that causes abnormally shaped blood cells and leads to leukaemia (myelodysplastic syndrome)</p><p>&nbsp;</p><p><strong>Discolouration of urine and other tissues</strong></p><p>Mitoxantrone may cause a blue-green colouration to the urine for 24 hours after administration. A bluish disolouration of the whites of your eyes, skin and nails may also occur.</p><p><strong>Contraception in men and women</strong></p><p>Men must not father a child and should use contraceptive measures during and at least 6 months after therapy. Women of childbearing potential should have a negative pregnancy test prior to each dose, and use effective contraception during therapy and for at least 4 months after cessation of therapy. If this medicine is</p><p>&nbsp;</p><p>used during pregnancy or if you become pregnant while taking this medicine, inform your doctor as there may be risks to the foetus.</p><p><strong>Fertility</strong></p><p>This medicine might increase the risk for transitory or persistent absence of menstruation (amenorrhoea) in women of childbearing age.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>There is little experience in children and adolescents.</p><p>Do not give this medicine to children and adolescents from birth up to age of 18 years as safety and efficacy in children and adolescents have not been established.</p><p><strong>Other medicines and Mitoxantron &ldquo;EBEWE&rdquo;</strong></p><p>Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines. It is particularly important that you mention any of the following medicines.</p><p>Medicines which may increase the risk of side effects with Mitoxantron &ldquo;EBEWE&rdquo;:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines that can damage your heart (e.g. anthracyclines).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines that suppress the bone marrow&#39;s production of blood cells and platelets (myelosuppressive agents).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines that suppress your immune system (immunosuppressive agents).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Antivitamin K, in particular if you are taking Mitoxantron &ldquo;EBEWE&rdquo; because you have cancer.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Topoisomerase II inhibitors (a groups of anticancer medicines including mitoxantrone) in combination with other chemotherapy and/or radiotherapy. These can cause:</p><p>o&nbsp; cancer of white blood cells (acute myeloid leukaemia, AML);</p><p>o&nbsp; a bone marrow disorder that causes abnormally shaped blood cells and leads to leukaemia (myelodysplastic syndrome).</p><p>&nbsp;</p><p>Ask your doctor or pharmacist if you are not sure whether your medicine is one of the medicines listed above.</p><p>These medicines should be used with care or may need to be avoided during your treatment with Mitoxantron &ldquo;EBEWE&rdquo;. If you are taking any of these, your doctor might need to prescribe an alternative medicine for you.</p><p>You should also tell your doctor if you are already taking Mitoxantron &ldquo;EBEWE&rdquo; and you are prescribed a new medicine that you have not already taken at the same time as Mitoxantron &ldquo;EBEWE&rdquo;.</p><p>Vaccinations and immunisation (protection against the vaccination substances) may not work during treatment with Mitoxantron &ldquo;EBEWE&rdquo; and for three months after the end of treatment.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before you are given this medicine.</p><p>&nbsp;</p><p><em>Pregnancy</em></p><p>Mitoxantron &ldquo;EBEWE&rdquo; may cause damage to your unborn child.</p><p>Therefore you should avoid becoming pregnant. Mitoxantron &ldquo;EBEWE&rdquo; must not be used during pregnancy for treatment of multiple sclerosis (specifically in the first three months of the pregnancy).</p><p>&nbsp;</p><p>If you become pregnant during the treatment with Mitoxantron &ldquo;EBEWE&rdquo;, you must tell your doctor immediately and stop treatment with Mitoxantron &ldquo;EBEWE&rdquo;.</p><p>You should avoid becoming pregnant. Men must use an effective method of contraception during the treatment and for at least 6 months after discontinuing the treatment. Women of child-bearing potential should have a negative pregnancy test prior to each dose and must practise effective contraception for at&nbsp; least 4 months after stopping the treatment with Mitoxantron &ldquo;EBEWE&rdquo;.</p><p>&nbsp;</p><p><em><u>Breast-feeding</u></em></p><p>Mitoxantron &ldquo;EBEWE&rdquo; is secreted into breast milk and may cause serious adverse reactions in your baby. You must not breast-feed while using mitoxantrone and for up to one month after the last administration.</p><p><em><u>Fertility</u></em></p><p>Mitoxantron &ldquo;EBEWE&rdquo; might increase the risk for transient or persistent absence of menstruation (amenorrhoea) in women of childbearing age. Therefore you should talk to your doctor if you are planning to become pregnant in the future; your eggs may need to be frozen. In men, no data are available. However, in male animals, damage to the testes and decreased sperm counts were observed.</p><p><strong>Driving and using machines</strong></p><p>Mitoxantron &ldquo;EBEWE&rdquo; has a minor effect on your ability to drive and use machines. This is caused by possible side effects, such as confusion or feeling tired (see section 4).</p><p>If you suffer from these side effects, do not drive any vehicles and/or use any machines.</p><p><strong>Mitoxantron &ldquo;EBEWE&rdquo;&nbsp; contains sodium. </strong></p><p>Please tell your doctor if you are on a controlled sodium diet.</p><p>1 vial of 5 ml solution contains 0.739 mmol (17.10mg) sodium.</p><p>1 vial of 10 ml solution contains 1.478 mmol (34.14mg) sodium.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Mitoxantron &ldquo;EBEWE&rdquo; will be given to you under supervision of a doctor experienced in the use of cytotoxic chemotherapy agents. It must always be administered as an intravenous infusion (in a vein) and must always be diluted before use. The infusion liquid may leak out of the vein into the tissue (extravasation). If this happens, the infusion must be stopped and restarted in another vein.</p><p>You should avoid contact with Mitoxantron &ldquo;EBEWE&rdquo;, especially on your skin, mucous membranes (moist body surfaces, such as the lining of the mouth) and eyes.</p><p>&nbsp;</p><p>The individual dose of Mitoxantron &ldquo;EBEWE&rdquo; is calculated by your doctor.</p><p>The recommended dose is based on your body surface area, which is calculated in square metres (m2) using your height and weight. In addition your blood will be tested regularly during the treatment. The dosage of the medicine will be adjusted in accordance with the results of these tests.</p><p>&nbsp;</p><p>The usual dose is:</p><p>&nbsp;</p><p><em>Metastatic Breast Cancer, Non-Hodgkin&rsquo;s Lymphomas</em></p><p>If Mitoxantron &ldquo;EBEWE&rdquo; is used alone:</p><p>The recommended initial dosage of Mitoxantron &ldquo;EBEWE&rdquo; is 14 mg/m2 of body surface area, given as a single intravenous dose, which may be repeated at 21-day intervals, if your blood values have returned to acceptable levels.</p><p>&nbsp;</p><p>A lower initial dosage (12 mg/m2 or less) is recommended in patients with low bone marrow reserves e.g. due to prior chemotherapy or poor general condition.</p><p>&nbsp;</p><p>Your doctor will decide precisely which subsequent dosage you need.</p><p>For subsequent courses, the prior dose can usually be repeated if white blood cell and platelet counts have returned to normal levels after 21 days.</p><p>Combination therapy (if used with other agents)</p><p>Mitoxantron &ldquo;EBEWE&rdquo; has been given as part of combination therapy. In metastatic breast cancer, combinations of Mitoxantron &ldquo;EBEWE&rdquo; with other cytotoxic agents including cyclophosphamide and 5- fluorouracil or methotrexate and mitomycin C have been shown to be effective.</p><p>Mitoxantron &ldquo;EBEWE&rdquo; has also been used in various combinations for non-Hodgkin&rsquo;s lymphoma; however, data are presently limited and specific regimens cannot be recommended. -</p><p>As a guide, when Mitoxantron &ldquo;EBEWE&rdquo; is used in combination chemotherapy, the initial dose of Mitoxantron &ldquo;EBEWE&rdquo; should be reduced by 2-4 mg/m2 below the doses recommended when Mitoxantron &ldquo;EBEWE&rdquo; is used alone.</p><p>&nbsp;</p><p><em>Acute myeloid leukemia</em></p><p>If used alone for recurrence (return of the cancer)</p><p>The recommended dosage for remission induction is 12 mg/m2 of body surface area, given as a single intravenous dose daily for five consecutive days (total of 60 mg/m2&nbsp; per 5 days).</p><p>&nbsp;</p><p>If used with other agents against cancer:</p><p>Your doctor will decide exactly what dosage you need. This dose might be adjusted if:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The combination of medicines reduces the production of white and red blood cells as well as platelets in your bone marrow more than Mitoxantron &ldquo;EBEWE&rdquo; used alone;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have serious liver or kidney problems.</p><p>&nbsp;</p><p><em>Treatment of blast crisis in (chronic) myeloid leukaemia</em></p><p>Used alone for recurrence</p><p>The recommended dosage in relapse is 10 to 12 mg/m2 body surface area given as a single intravenous dose daily over 5 consecutive days (total of 50 to 60 mg/m2).</p><p><em>Advanced castrate-resistant prostate cancer </em>The recommended dosage of Mitoxantron &ldquo;EBEWE&rdquo; is 12 to 14 mg/m2&nbsp; given as a short intravenous infusion every 21 days, in combination with low oral doses of corticosteroids (hormonal medicines that suppress the immune system).</p><p>&nbsp;</p><p><em>Multiple Sclerosis</em></p><p>Mitoxantron &ldquo;EBEWE&rdquo; will be given to you under the supervision of a doctor experienced in the use of cytotoxic chemotherapeutic agents for the treatment of multiple sclerosis.</p><p>The recommended dosage of mitoxantrone is usually 12 mg/m2 body surface area given as a short (approximately 5 to 15 minutes) intravenous infusion that may be repeated every 1 to 3 months. The maximum lifetime cumulative dose should not exceed 72 mg/m2.</p><p>&nbsp;</p><p>If mitoxantrone is administered repeatedly, dosing adjustments should be guided by extent and duration of the reduction in the number of white and red blood cells as well as platelets in your blood.</p><p>&nbsp;</p><p><strong>Elderly patients</strong></p><p>Elderly patient should receive doses at the low end of the dosing range due to possible reduced liver, kidney or heart function and of possible illness or treatment with other medicines.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Mitoxantron &ldquo;EBEWE&rdquo; can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>The most serious side effects are damage to the heart (myocardial toxicity) and myelosuppression (reduced activity of the bone marrow). <strong>Some side effects could be serious</strong></p><p><em>If any of the following happen, tell your doctor immediately:</em></p><p><em>&nbsp;</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your skin becomes pale and you feel weak or experience sudden shortness of breath, this can be sign of a reduction in red blood cells.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unsual bruising or bleeding, such as coughing up blood, blood in your vomit or urine, or black stools (potential sign of platelet reduction).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; New or worsening breathing difficulties.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest pain, breathlessness, changes in your heartbeat (fast or slow), fluid retention (swelling) in the ankles or legs (potential signs or symptoms of heart problems).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe itchy rash (hives), swelling of the hands, feet, ankles, face, lips, mouth or throat (which may cause difficulty in swallowing or breathing), or if you feel you like you are going to faint, these may be signs of severe allergic reaction.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever or infections</p><p>&nbsp;</p><p><strong>For patients being treated for cancer:</strong></p><p><strong>&nbsp;</strong></p><p><strong>Very common (may affect more than 1 in 10 people):</strong></p><p><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>Infections</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low number of red blood cells which can cause a feeling of tiredness and shortness of breath (anaemia).&nbsp; You may require a blood transfusion.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low number of a special form of white blood cells (neutrophils and leukocytes)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea (feeling sick)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting (being sick)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hair loss</p><p>&nbsp;</p><p><strong>Common (may affect up to 1 in 10 people):</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low level of platelets &ndash; which may cause bleeding or bruising.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low number of special white blood cells (granulocytes).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tiredness, weakness and lack of energy.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of appetite</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart attack</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the mouth and lips</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Congestive heart failure (severe condition where the heart cannot anymore pump enough blood)</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Uncommon (may affect up to 1 in 100 people):</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduced activity of the bone marrow. Your bone marrow can be more depressed or be depressed for a longer period if you have had chemotherapy or radiotherapy.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Insufficient production of bloods cells in the bone marrow (bone marrow failure)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal number of white blood cells.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe allergic reactions (anaphylactic reaction including anaphylactic shock) - you may experience a sudden itchy rash (hives), swelling of the hands, feet, ankles, face, lips, mouth or throat, which may cause difficulty in swallowing or breathing, and you may feel you are going to faint).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections of the upper airways.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections of the urinary tract.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood poisoning (sepsis).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections caused by microorganisms which do not normally cause diseases with a healthy immune system (opportunistic infections).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cancer of the white blood cells (acute myeloid leukemia (AML)).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bone marrow abnormality which causes the formation of abnormal blood cells which leads to leukaemia (myelodisplastic syndrome (MDS)).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in weight.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Metabolic disturbances (tumour lysis syndrome).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anxiety.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confusion.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tingling sensation.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irregular heart beat or slowed heartbeat.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal electrocardiogram.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduction of the volume of blood that the left ventrical can pump, with no symptoms.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bruising.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heavy bleeding.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood pressure.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal pain.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding in your stomach or bowels, this may include blood in vomit, bleeding when emptying the bowels or black tarry stool.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mucosal inflammation.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the pancreas.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver abnormalities.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin inflammations (erythema).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nail abnormalities (e.g. detachment of the nail fro the nail bed, changes in nail texture and structure).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes to the colour of the whites of the eyes.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin discolouration.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Leakage of fluid into surrounding tissue (extravasation): o Reddening (erythema).</p><p>o&nbsp; Swelling.</p><p>o&nbsp; Pain.</p><p>o&nbsp; Burning feeling and/or discolouration of the skin.</p><p>o&nbsp; Death of tissue cells which can lead to the need to remove dead cells and skin transplantation.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal results of blood tests to check liver and kidney functions (raised aspartate aminotransferase levels, elevated creatinine and urea nitrogen concentration in the blood).</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Damage to the kidneys, causing swelling and weakness (nephropathy).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urine discolouration.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling (oedema).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Taste disturbances.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal absence of menstruation (amenorrhoea).</p><p>&nbsp;</p><p><strong>Rare (may affect up to 1 in 1000 people):</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Damages to the heart muscle preventing it from pumping properly (cardiomyopathy)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lung inflammation (pneumonia).</p><p>&nbsp;</p><p><strong>For patients being treated for Multiple Sclerosis: </strong></p><p><strong>Very Common (may affect more than 1 in 10 people)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections, including infections of the upper airways and urinary tract.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea (feeling sick).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hair loss.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnomal absence of menstruation (amenorrhea).</p><p>&nbsp;</p><p><strong>Common (may affect up to 1 in 10 people)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low number of red blood cells which can cause a feeling of tiredness and shortness of breath (anaemia). You may require a blood transfusion.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low number of special white blood cells (granulocytes and leukocytes).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting (being sick).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the mouth and lips.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal number of white blood cells.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irregular heart beat.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal electrocardiogram.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduction of the volume of blood that the left ventrical can pump, with no symptoms.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal results of blood tests to check liver function (raised aspartate aminotransferase levels).</p><p>&nbsp;</p><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lung inflammation (pneumonia).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood poisoning (sepsis).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections caused by microorganisms which do not normally cause diseases with a healthy immune system (opportunistic infections).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cancer of the white blood cells (acute myeloid leukemia (AML)).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A bone marrow abnormality which causes the formation of abnormal blood cells which leads to leukaemia (myelodisplastic syndrome (MDS)).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Insufficient production of blood cells in the bone marrow (bone marrow failure).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduced activity of the bone marrow. Your bone marrow can be more depressed or be depressed for a longer period if you have had chemotherpy or radiotherapy.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low level of platelets &ndash; which may cause bleeding or bruising.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low number of special white blood cells (neutrophils).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe allergic reaction (anaphylactic reaction including anyphylactic shock) &ndash; you may experience a sudden itchy rash (hives), swelling of the hands, feet, ankles, face, lips, mouth or throat, which may cause difficulty in swallowing or breathing, and you may feel you are going to faint).</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of appetite.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in weight.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anxiety.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confusion.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tingling sensation.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tiredness, feeling weak and having no energy.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe condition where the heart cannot anymore pump enough blood (congestive heart failure).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Damages to the heart muscle preventing it from pumping properly (cardiomyopathy).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Slowed heart beat.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart attack.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unusal bruising.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heavy bleeding.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood pressure.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal pain.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding in your stomach or bowels, this may include blood in vomit, bleeding when emptying the bowels or black tarry stool.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mucosal inflammation.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the pancreas.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver abnormalities.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nail abnormalities (e.g. detachment of the nail fro the nail bed, changes in nail texture and structure).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes to the colour of the whites of the eyes.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin discolouration.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Leakage of fluid into surrounding tissue (extravasation):</p><p>o&nbsp;&nbsp; Reddening (erythema).</p><p>o&nbsp;&nbsp; Swelling.</p><p>o&nbsp;&nbsp; Pain.</p><p>o&nbsp;&nbsp; Burning feeling and/or discolouration of the skin.</p><p>o&nbsp;&nbsp; Death of tissue cells which can lead to the need to remove dead cells and skin transplantation.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal results of blood tests to check liver and kidney functions (elevated creatinine and urea nitrogen concentration in the blood).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Damage to the kidneys, causing swelling and weakness (nephropathy).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urine discolouration.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling (oedema).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden death.</p><p>&nbsp;</p><p><strong>Rare (may affect up to 1 in 1,000 people)</strong></p><p>None.</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the label after EXP. The expiry date refers to the last day of that month.</p><p>Store below 25&deg;C. Do not freeze.</p><p><u>Shelf life:</u></p><p>Packaged for sale: 2 years (before reconstitution). Diluted solutions: up to 24 hours.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is mitoxantrone (as hydrochloride). Each ml contains 2 mg mitoxantrone (as hydrochloride).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: sodium chloride, sodium acetate, glacial acetic acid, sodium sulphate, hydrochloric acid (for pH adjustment), water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Mitoxantron “Ebewe” is a clear blue solution and is free of particles. It is provided in colourless glass vials in a carton. 1, 5 or 10 identical vials containing 10 mg mitoxantron per 5 ml or 20 mg mitoxantron per 10 ml are packed in one cardboard box.

Pack sizes: 1x5 ml, 5x5 ml, 10x5 ml, 1x10 ml, 5x10 ml and 10x10 ml.

Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Ebewe Pharma Ges.m.b.H. Nfg.KG</p><p>&nbsp;A-4866 Unterach, AUSTRIA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                06/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي عقار ميتوكسانترون &quot;إيبيفيه&quot; على المادة الفعَّالة ميتوكسانترون. ينتمي عقار ميتوكسانترون &quot;إيبيفيه&quot; إلى مجموعة من الأدوية تُعرف بالأدوية المضادة للأورام أو المُضادة للسرطان، وهو ينتمي أيضًا إلى مجموعة فرعية من الأدوية المُضادة للسرطان تُسمى الأنثراسيكلينات. يمنع عقار ميتوكسانترون &quot;إيبيفيه&quot; نمو الخلايا السرطانية، مما سيُؤدي إلى موتها في نهاية الأمر. يعمل هذا الدَّواء أيضًا على كبت الجهاز المناعي وبفضل هذا التَّأثير، يستخدم لعلاج نوع محدد من التَّصلب المتعدد عندما لا تُوجد خيارات علاج بديلة.</p><p dir="RTL">يُستخدم عقار ميتوكسانترون &quot;إيبيفيه&quot; في علاج الآتي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرحلة متقدمة (السرطان النقيلي) من سرطان الثدي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أحد أنواع سرطان العقد الليمفاوية (سرطان الغدد الليمفاوية غير الهودجكين).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الدَّم حيث ينتج النخاع العظمي (الأنسجة الإسفنجية داخل العظام الكبيرة) العديد من خلايا الدَّم البيضاء (سرطان الدَّم النخاعي الحاد).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان خلايا الدَّم البيضاء (سرطان الدَّم النخاعي المزمن) في مرحلة يصعب فيها التَّحكم في عدد خلايا الدَّم البيضاء (النوبة الأرومية). يُستَخدَم عقار ميتوكسانترون &quot;إيبيفيه&quot; بمصاحبة منتجات دوائية أخرى للدَّواعي التَّالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم ناجم عن سرطان البروستاتا في إحدى المراحل المتقدمة لسرطان البروستاتا بمصاحبة الكورتيكوستيرويدات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تصلُّب متعدد انتكاسي نشط للغاية تصاحبه إعاقة سريعة التَّطور والتي ليس لها خيارات علاجية بديلة قائمة (انظر قسمي: 2 و3).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تستعمل عقار ميتوكسانترون &quot;إيبيفيه&quot; في الحالات التَّالية:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه ميتوكسانترون أو تجاه أي مكون من المكونات الأخرى بهذا الدَّواء (المدرجة في قسم: 6).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه السلفيت.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بأحد أنواع الربو (الربو الشُّعَبي) وحساسية تجاه السلفيت.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ مرضعًا (انظري قسم: &quot;الحمل والرَّضاعة الطبيعية&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>للاستخدام كعلاج لمرض التَّصلب المتعدد</u><u>:</u></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملًا.</p><p><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">يجب إعطاء عقار ميتوكسانترون &quot;إيبيفيه&quot; تحت إشراف طبيب ذي خبرة في استخدام أدوية علاج السرطان والتي تكون سامة للخلايا (أدوية العلاج الكيميائي السامة للخلايا).</p><p dir="RTL">ينبغي إعطاء عقار ميتوكسانترون &quot;إيبيفيه&quot; عن طريق التسريب البطيء والتَّدفق الجيد في الوريد. يجب عدم إعطاء عقار ميتوكسانترون &quot;إيبيفيه&quot; أسفل الجلد أو في العضل أو في الشريان. قد يحدث تلف شديد بالأنسجة الموضعية في حال تسرب عقار ميتوكسانترون &quot;إيبيفيه&quot; إلى ما حوله من أنسجة (تسرب خارج الوريد) أثناء الإعطاء.</p><p dir="RTL">كما يجب عدم حقن عقار ميتوكسانترون &quot;إيبيفيه&quot; في الفراغ الموجود أسفل المخ أو النُّخاعِ الشوكي (حقن داخل القراب) فقد يُؤدي ذلك إلى حدوث إصابة شديدة يصحبها قصور دائم.</p><p><strong>تحدَّث إلى طبيبك أو الصيدلي أو الممرض(ة) قبل استخدام عقار ميتوكسانترون &quot;إيبيفيه&quot; في الحالات الآتية:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل بالكبد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل بالكلى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد استخدمت عقار ميتوكسانترون &quot;إيبيفيه&quot; من قبل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان قلبك لا يعمل بكفاءة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا خضعت من قبل لعلاج إشعاعي على الصدر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت بالفعل تستخدم أدوية أخرى لها تأثير على قلبك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا خضعت سابقًا للعلاج بالأنثراسيكلينات أو الأنثراسينديونات، مثل: داونوروبيسين أو دوكسوروبيسين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان نخاعك العظمي لا يعمل كما ينبغي (كبت النخاع العظمي) أو إذا كانت حالتك الصحية العامة سيئة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بعدوى. ينبغي علاج هذه العدوى قبل استخدام عقار ميتوكسانترون &quot;إيبيفيه&quot;.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعتزم الحصول على لقاح أو تطعيم أثناء العلاج. قد لا تجدي اللقاحات والتطعيمات نفعًا أثناء العلاج بعقار ميتوكسانترون &quot;إيبيفيه&quot; ولمدة 3 أشهر بعد انتهاء العلاج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملًا أو إذا كنتِ تحاولين أنتِ وشريككِ الإنجاب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ مرضعًا. ينبغي عليك التَّوقف عن ممارسة الرضاعة الطبيعيَّة قبل استخدام عقار ميتوكسانترون &quot;إيبيفيه&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي الخاص بك أو الممرض(ة) على الفور إذا أُصبت بأي من العلامات أو الأعراض التَّالية أثناء العلاج بعقار ميتوكسانترون &quot;إيبيفيه&quot;:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى، عدوى، الإصابة بكدمات أو نزيف غير معروف الأسباب، ضعف وسهولة الشعور بالتعب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عُسْر التَّنَفُّس (بما في ذلك عُسْرُ التَّنَفُّس أثناء الليل)، سعال، احتباس السوائل (تورم) في الكاحلين أو الساقين، خفقان القلب (عدم انتظام ضربات القلب). قد يحدث هذا إما أثناء العلاج بعقار ميتوكسانترون &quot;إيبيفيه&quot; أو بعد مرور أشهر إلى أعوام عليه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يحتاج طبيبك إلى تعديل العلاج الخاص بك أو وقف عقار ميتوكسانترون &quot;إيبيفيه&quot; بشكل مؤقت أو دائم.</p><p><strong>اختبارات الدَّم قبل وأثناء العلاج بعقار ميتوكسانترون &quot;إيبيفيه&quot;</strong></p><p dir="RTL">قد يُؤثر عقار ميتوكسانترون &quot;إيبيفيه&quot; على عدد خلايا الدَّم لديك. قبل البدء في استخدام عقار ميتوكسانترون &quot;إيبيفيه&quot; وأثناء العلاج، سيجري طبيبك اختبار دم لحساب عدد خلايا الدَّم لديك. سيجري طبيبك اختبارات دم بشكل أكثر تكرارًا؛ حيث سيراقب عدد خلايا الدَّم البيضاء (ابيضاض العدلات) في الدَّم على وجه الخصوص:</p><p dir="RTL">&middot;&nbsp;&nbsp;<span style="text-align:unset">إذا كان لديك انخفاض في عدد نوع محدد من خلايا الدَّم البيضاء (العدلات) (أقل من 1500 خلية/ مللي متر مكعب).</span></p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;<span style="text-align:unset">إذا كنت تستخدم عقار ميتوكسانترون &quot;إيبيفيه&quot; بجرعات مرتفعة (&gt;14 مجم/ متر مربع</span><sup style="text-align:unset"> </sup><span style="text-align:unset">في اليوم &times; 3 أيام).</span></p><p>&nbsp;</p><p dir="RTL"><strong>اختبارات وظائف القلب قبل وأثناء العلاج بعقار ميتوكسانترون &quot;إيبيفيه&quot;</strong></p><p dir="RTL">قد يضر عقار ميتوكسانترون &quot;إيبيفيه&quot; قلبك ويُؤدي إلى تدهور وظائف القلب لديك أو فشل القلب في حالات أكثر شدة. ستصبح أكثر عرضة للإصابة بهذه الآثار الجانبية إذا استخدمت جرعات أعلى من عقار ميتوكسانترون &quot;إيبيفيه&quot; أو:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان قلبك لا يعمل بكفاءة.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا خضعت من قبل لعلاج إشعاعي على الصدر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت بالفعل تستخدم أدوية أخرى لها تأثير على قلبك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; إذا خضعت سابقًا للعلاج بالأنثراسيكلينات أو الأنثراسينديونات، مثل: داونوروبيسين أو دوكسوروبيسين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيجري طبيبك اختبارات لوظائف القلب قبل بدئك في استخدام عقار ميتوكسانترون &quot;إيبيفيه&quot; وعلى فترات منتظمة أثناء العلاج. إذا تلقيت عقار ميتوكسانترون &quot;إيبيفيه&quot; لعلاج التصلب المتعدد، سيفحص طبيبك وظائف القلب لديك قبل بدء العلاج، وذلك قبل كل جرعة تالية وسنويًّا لمدة تصل إلى 5 أعوام بعد انتهاء العلاج.</p><p><strong>سرطان الدَّم النخاعي الحاد ومتلازمة خلل التنسّج النخاعي</strong></p><p dir="RTL">قد تتسبب إحدى مجموعات الأدوية المضادة لمرض السرطان (مثبطات توبوايزوميريز 2)، بما في ذلك عقار ميتوكسانترون &quot;إيبيفيه&quot;، في الإصابة بالأمراض التَّالية عند استخدامها بمفردها ولا سيما بمصاحبة علاج كيميائي آخر و/ أو علاج إشعاعي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان خلايا الدَّم البيضاء (سرطان الدَّم النخاعي الحاد).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أحد اضطرابات النخاع العظمي التي تتسبب في تكوّن خلايا دم غير طبيعية الشكل وتؤدي إلى الإصابة بسرطان الدَّم (متلازمة خلل التَّنسج النخاعي).</p><p dir="RTL">&nbsp;</p><p><strong>تغير لون البول وأنسجة أخرى</strong></p><p dir="RTL">قد يسبب ميتوكسانترون تحول لون البول إلى الأخضر المائل للزرقة لمدة 24 ساعة بعد الإعطاء. قد يتغير أيضًا لون بياض عينيك وجلدك وأظافرك إلى اللون الأزرق.</p><p><strong>منع الحمل في الرجال والسيدات</strong></p><p dir="RTL">يجب على الرجال عدم الإنجاب وينبغي استخدام تدابير منع الحمل أثناء العلاج وبعده بستة أشهر على الأقل. ينبغي على السيدات ممن لديهن القدرة على الحمل أن تكون نتيجة اختبار حملهن سلبية قبل كل جرعة وينبغي عليهن استخدام وسائل منع حمل فعَّالة أثناء العلاج ولمدة 4 أشهر على الأقل بعد وقف العلاج. إذا استُخدم هذا الدَّواء أثناء فترة الحمل أو إذا أصبحتِ حاملًا أثناء تناوُل هذا الدَّواء، فأخبري طبيبكِ فمن المحتمل أن تكون هناك مخاطر على الجنين.</p><p><strong>الخصوبة</strong></p><p dir="RTL">قد يزيد هذا الدَّواء من خطر الانقطاع العابر أو الدائم للحيض (الطمث) في السيدات ممن هن بسن الإنجاب.</p><p dir="RTL">&nbsp;</p><p><strong>الأطفال والمراهقون</strong></p><p dir="RTL">هناك القليل من الخبرة بشأن الاستخدام في الأطفال والمراهقين.</p><p dir="RTL">لا تعط هذا الدَّواء للأطفال والمراهقين بدءًا من الولادة وحتى عمر 18 عامًا؛ إذ لم يتم التَّأكد من أمانه وفعَّاليته في الأطفال والمراهقين.</p><p><strong>استعمال أدوية أخرى مع عقار ميتوكسانترون &quot;إيبيفيه&quot;</strong></p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تستخدم أو استخدمت مؤخرًا أو قد تستخدم أيَّة أدوية أخرى. إنه من المهم أن تذكر أيًّا من الأدوية التَّالية:</p><p dir="RTL">الأدوية التي قد تؤدي إلى زيادة خطورة حدوث آثار جانبية مع عقار ميتوكسانترون &quot;إيبيفيه&quot;:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية قد تلحق الضرر بقلبك (على سبيل المثال: الأنثراسيكلينات).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تقوم بكبت إنتاج النخاع العظمي لخلايا الدَّم والصفائح الدَّموية (الأدوية الكابتة للنخاع العظمي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تقوم بكبت جهازك المناعي (الأدوية الكابتة للمناعة).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة لفيتامين &quot;ك&quot;، لا سيما إذا كنت تستخدم عقار ميتوكسانترون &quot;إيبيفيه&quot; بسبب إصابتك بمرض السرطان.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات توبوايزوميريز 2 (مجموعة من الأدوية المضادة لمرض السرطان من ضمنها ميتوكسانترون) بمصاحبة علاج كيميائي آخر و/ أو علاج إشعاعي. قد يُسبب هذا:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp; سرطان خلايا الدَّم البيضاء (سرطان الدَّم النخاعي الحاد).</p><p dir="RTL">o&nbsp;&nbsp;&nbsp; أحد اضطرابات النخاع العظمي التي تتسبب في تكوّن خلايا دم غير طبيعية الشَّكل وتؤدي إلى الإصابة بسرطان الدَّم (متلازمة خلل التَّنسج النخاعي).</p><p dir="RTL">&nbsp;</p><p dir="RTL">استشر طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا مما إذا كان دواؤك قد ورد بقائمة الأدوية المذكورة أعلاه أم لا.</p><p dir="RTL">يجب استخدام هذه الأدوية بعناية أو تجنُّب تناوُل هذه الأدوية أثناء علاجك بعقار ميتوكسانترون &quot;إيبيفيه&quot;. إذا كنت تستخدم أيًّا من هذه الأدوية، فقد يحتاج طبيبك إلى وصف دواء بديل لك.</p><p dir="RTL">ينبغي عليك أيضًا إخبار طبيبك إذا كنت تستخدم بالفعل عقار ميتوكسانترون &quot;إيبيفيه&quot; ووُصف لك دواء جديد لم تستخدمه بعد بالتزامن مع عقار ميتوكسانترون &quot;إيبيفيه&quot;.</p><p dir="RTL">قد لا تجدي اللقاحات والتطعيمات (وقاية من مواد اللقاح) نفعًا أثناء العلاج بعقار ميتوكسانترون &quot;إيبيفيه&quot; ولمدة ثلاثة أشهر بعد انتهاء العلاج.</p><p dir="RTL">&nbsp;</p><p><strong>الحمل والرَّضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">إذا كنتِ حاملًا أو مرضعًا، أو تعتقدين أنكِ حامل أو تخططين لذلك، فاستشيري طبيبك أو الصيدلي الخاص بك قبل أن يتم إعطاؤك هذا الدَّواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الحمل</em></p><p>قد يُلحق عقار ميتوكسانترون &quot;إيبيفيه&quot; الضرر بجنينك.</p><p dir="RTL">لذا، يجب عليكِ تجنب الحمل. يجب عدم استخدام عقار ميتوكسانترون &quot;إيبيفيه&quot; أثناء فترة الحمل لعلاج التصلب المتعدد (تحديدًا خلال الثلاثة أشهر الأولى من الحمل).</p><p dir="RTL">إذا أصبحت حاملًا أثناء العلاج بعقار ميتوكسانترون &quot;إيبيفيه&quot;، يجب عليك إخبار طبيبك على الفور وإيقاف العلاج بعقار ميتوكسانترون &quot;إيبيفيه&quot;.</p><p dir="RTL">يجب عليكِ تجنب الحمل. يجب على الرجال استخدام إحدى الوسائل الفعَّالة لمنع الحمل أثناء العلاج ولمدة 6 أشهر على الأقل بعد وقف العلاج. ينبغي على السيدات ممن لديهن القدرة على الحمل أن تكون نتيجة اختبار حملهن سلبية قبل كل جرعة وينبغي عليهن استخدام وسائل منع حمل فعَّالة لمدة 4 أشهر على الأقل بعد وقف العلاج بعقار ميتوكسانترون &quot;إيبيفيه&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em><u>الرَّضاعة الطبيعية</u></em></p><p dir="RTL">يُفرَز عقار ميتوكسانترون &quot;إيبيفيه&quot; في لبن الأم وقد يسبب آثارًا جانبية خطيرة لطفلك. يجب عليكِ تجنُّب الإرضاع أثناء استخدامك لميتوكسانترون ولمدة تصل إلى شهر واحد بعد آخر إعطاء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em><u>الخصوبة</u></em></p><p dir="RTL">قد يزيد عقار ميتوكسانترون &quot;إيبيفيه&quot; من خطر الانقطاع العابر أو الدَّائم للحيض (الطمث) في السيدات ممن هن بسن الإنجاب. لذلك يجب عليكِ التَّحدث إلى طبيبكِ إذا كنتِ تخططين للحمل في المستقبل؛ فقد تكون هناك حاجة إلى تجميد بويضاتك. في الرجال، لا توجد بيانات متاحة. مع ذلك، تمت ملاحظة تضرر الخصيتين وانخفاض عدد الحيوانات المنوية في ذكور الحيوانات.</p><p dir="RTL">&nbsp;</p><p><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">عقار ميتوكسانترون &quot;إيبيفيه&quot; له تأثير طفيف في القدرة على القيادة واستخدام الآلات. هذا قد تسببه آثار جانبية محتملة، مثل ارتباك أو شعور بالتَّعب (انظر قسم: 4).</p><p dir="RTL">إذا كنت تعاني من هذه الآثار الجانبية، فلا تقم بقيادة أي مركبات و/ أو تستخدم أي آلات.</p><p dir="RTL"><strong>يحتوي عقار ميتوكسانترون </strong><strong>&quot;</strong><strong>إيبيفيه</strong><strong>&quot; </strong><strong>على الصوديوم</strong><strong>. </strong>يُرجى إخبار الطبيب إذا كنت تتبع نظامًا غذائيًّا منخفض الصوديوم (الملح).</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي الزجاجة الواحدة التي تحتوي على 5 مللي لتر من المحلول على 0.739 مللي مول (17.10 مجم) من الصوديوم. تحتوي الزجاجة الواحدة التي تحتوي على 10 مللي لتر من المحلول على 1.478 مللي مول (34.14 مجم) من الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيتم إعطاؤك عقار ميتوكسانترون &quot;إيبيفيه&quot; تحت إشراف طبيب ذي خبرة في استخدام العلاج الكيميائي السَّام للخلايا. يجب إعطاؤه دائمًا عن طريق التَّسريب الوريدي (في أحد الأوردة) ويجب تخفيفه دائمًا قبل الاستخدام. قد يتسرب سائل التَّسريب من الوريد ليصل إلى الأنسجة (تسرب خارج الوريد). إذا حدث هذا، يجب وقف التَّسريب والبدء من جديد في وريد آخر.</p><p dir="RTL">ينبغي عليك تجنب ملامسة عقار ميتوكسانترون &quot;إيبيفيه&quot;، خاصةً لجلدك، الأغشية المخاطية (أسطح الجسم الرطبة، مثل: بطانة الفم) والعينين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم قياس الجرعة الفردية من عقار ميتوكسانترون &quot;إيبيفيه&quot; من قبل طبيبك.</p><p dir="RTL">تعتمد الجرعة المُوصى بها على مساحة سطح الجسم لديك، والتي تُقاس بالمتر المربع باستخدام طولك ووزنك. بالإضافة إلى ذلك، سيتم فحص دمك بشكل منتظم أثناء العلاج. سيتم تعديل جرعة الدَّواء وفقًا لنتائج هذه الاختبارات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة المعتادة هي:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>سرطان الثدي المتقدم، سرطان الغدد الليمفاوية غير الهودجكن</em></p><p dir="RTL">في حالة استخدام عقار ميتوكسانترون &quot;إيبيفيه&quot; بمفرده:</p><p dir="RTL">تبلغ الجرعة الأولية الموصى بها من عقار ميتوكسانترون &quot;إيبيفيه&quot; والمستخدمة كعقار مفرد 14 مجم/ متر<sup> </sup>مربع من مساحة سطح الجسم، ويتم إعطاؤها كجرعة مفردة في الوريد ويمكن تكرارها على فترات زمنية قدرها 21 يومًا، إذا كانت قيم الدَّم لديك قد عادت إلى مستويات مقبولة.</p><p dir="RTL">يُوصى بجرعة أولية أقل (12 مجم/ متر مربع أو أقل) في المرضى ممن لديهم احتياطي منخفض من النخاع العظمي، على سبيل المثال: نتيجة العلاج الكيميائي المسبق أو سوء الحالة العامة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيحدد طبيبك بدقة الجرعة التَّالية التي تحتاج إليها.</p><p dir="RTL">بالنسبة لدورات العلاج اللاحقة، يمكن عادة تكرار الجرعات السَّابقة إذا عاد تعداد كُرَيَّات الدَّم البيضاء والصفائح الدَّموية إلى المستويات الطبيعية بعد 21 يومًا حينها.</p><p dir="RTL">العلاج المركب (في حال استخدام العقار مع أدوية أخرى)</p><p dir="RTL">يتم إعطاء عقار ميتوكسانترون &quot;إيبيفيه&quot; كجزء من العلاج المركب. في حالة سرطان الثدي المتقدم، فقد ثبتت فعَّالية جمع عقار ميتوكسانترون &quot;إيبيفيه&quot; مع الأدوية الأخرى السَّامة للخلايا بما في ذلك، سيكلوفوسفاميد و5- فلورويوراسيل، أو ميثوتريكسات وميتوميسين-سي.</p><p dir="RTL">استُخدم عقار ميتوكسانترون &quot;إيبيفيه&quot; أيضًا في مجموعات علاج متعددة لعلاج سرطان الغدد الليمفاوية غير الهودجكين، ومع ذلك فإنَّ البيانات محدودة في الوقت الحالي ولا يمكن التوصية باستخدام أنظمة جرعات محددة. -</p><p dir="RTL">كدليل استرشادي، عند استخدام عقار ميتوكسانترون &quot;إيبيفيه&quot; ضمن مجموعة أدوية علاج كيميائي، ينبغي خفض الجرعة الأولية لعقار ميتوكسانترون &quot;إيبيفيه&quot; بمقدار 2-4 مجم/متر مربع أقل من&nbsp; الجرعات المُوصى بها عند استخدام عقار ميتوكسانترون &quot;إيبيفيه&quot; بمفرده.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>سرطان الدَّم النخاعي الحاد</em></p><p dir="RTL">في حال استخدامه بمفرده عند تكرار حدوث المرض (عودة السرطان).</p><p dir="RTL">تبلغ الجرعة الموصى بها لتحفيز الهدأة 12 مجم/ متر مربع من مساحة سطح الجسم، يتم إعطاؤها كجرعة مفردة عن طريق الوريد يوميًّا لمدة خمسة أيام متتالية (بإجمالي 60 مجم/ متر مربع في 5 أيام).</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حال استخدامه مع أدوية أخرى ضد مرض السرطان:</p><p dir="RTL">سيحدد طبيبك الجرعة التي تحتاج إليها بالضبط. قد يتم تعديل هذه الجرعة في الحالات الآتية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا خفضت مجموعة الأدوية المعالجة من إنتاج خلايا الدَّم البيضاء والحمراء والصفائح الدَّموية في النخاع العظمي لديك أكثر منها عند استخدام عقار ميتوكسانترون &quot;إيبيفيه&quot; بمفرده.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك مشاكل بالكبد أو الكلى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>علاج النوبة الأرومية في سرطان الدَّم النخاعي </em><em>(</em><em>المُزمِن</em><em>).</em></p><p dir="RTL">يُستخدم بمفرده عند تكرار حدوث المرض.</p><p dir="RTL">تبلغ الجرعة المُوصى بها عند حدوث انتكاس 10 إلى 12 مجم/ متر مربع من مساحة سطح الجسم ويتم إعطاؤها على هيئة جرعة مفردة عن طريق الوريد يوميًّا لمدة 5 أيام متتالية (إجمالي 50 إلى 60 مجم/ متر مربع).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>المراحل المتقدمة من سرطان البروستاتا المقاوم للإخصاء </em>تبلغ الجرعة الموصى بها من عقار ميتوكسانترون &quot;إيبيفيه&quot; 12 إلى 14 مجم/ متر مربع ويتم إعطاؤها في هيئة تسريب لفترة قصيرة عن طريق الوريد كل</p><p dir="RTL">21 يومًا، بمصاحبة جرعات فموية منخفضة من الكورتيكوستيرويدات (أدوية هرمونية تكبت استجابة الجهاز المناعي).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>التَّصلب المتعدد</em></p><p dir="RTL">سيتم إعطاؤك عقار ميتوكسانترون &quot;إيبيفيه&quot; تحت إشراف طبيب ذي خبرة في استخدام أدوية العلاج الكيميائي السَّام للخلايا لعلاج التصلب المتعدد.</p><p dir="RTL">عادة ما تبلغ الجرعة المُوصى بها من ميتوكسانترون 12 مجم/ متر مربع من مساحة سطح الجسم ويتم إعطاؤها في هيئة تسريب لفترة قصيرة (5 إلى 15 دقيقة تقريبًا) عن طريق الوريد ويمكن تكرارها كل شهر إلى 3 أشهر. يجب أَلَّا تتجاوز الجرعة القصوى المتراكمة مدى الحياة 72 مجم/ متر مربع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حال إعطاء ميتوكسانترون بشكل متكرر، ينبغي الاسترشاد فيما يخص تعديل الجرعة بدرجة الانخفاض ومدته في عدد خلايا الدَّم البيضاء والحمراء بالإضافة إلى الصفائح الدَّموية في دمك.</p><p dir="RTL">&nbsp;</p><p><strong>المرضى من كبار السن</strong></p><p dir="RTL">ينبغي على المرضى من كبار السن تلقي الجرعات الموجودة في أقل نطاق من الجرعة؛ نظرًا لاحتمال انخفاض وظائف الكبد أو الكُلى أو القلب لديهم واحتمال إصابتهم بأحد الأمراض أو علاجهم بأدوية أخرى.</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشيري طبيبك أو الصيدلي أو الممرض(ة) الخاص(ة) بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب عقار ميتوكسانترون &quot;إيبيفيه&quot; آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تشمل الآثار الجانبية الأشد خطورة، تلفًا بالقلب (تسمم عضلة القلب) وكبت النخاع العظمي (انخفاض نشاط النخاع العظمي). <strong>بعض الآثار الجانبية قد تكون خطيرة</strong></p><p dir="RTL"><em>أخبر طبيبك فورًا، إذا حدث أي من التالي</em><em>:</em></p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبح جلدك شاحبًا وكنت تشعر بالضعف أو تعاني من ضيق مفاجئ بالتَّنفس، فقد تكون هذه علامة على انخفاض خلايا الدَّم الحمراء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود كدمات غير معتادة أو نزيف، مثل: سعال مصحوب بدم، وجود دم في القيء أو البول، أو براز أسود (علامة محتملة تدل على انخفاض الصفائح الدموية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التَّنفس سواء جديدة أو تفاقمية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالصدر، عُسْر التَّنَفُّس، تغيرات في ضربات القلب (تسارع الضربات أو بطئها)، احتباس السوائل (تورم) في الكاحلين أو الساقين (علامات أو أعراض محتملة لوجود مشاكل في القلب).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي مصحوب بحكة (شرى [أرتكاريا])، تورم اليدين، القدمين، الكاحلين، الوجه، الشفتين، الفم أو الحلق (مما قد يُسبب صعوبة في البلع أو التنفس)، أو إذا شعرت بأنك ستصاب بالإغماء، قد تكون علامات تفاعلات حساسية شديدة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى أو عدوى.</p><p dir="RTL">&nbsp;</p><p><strong>للمرضى الذين يتم علاجهم من مرض السرطان:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة جدًّا </strong><strong>(</strong><strong>قد تُؤثر على أكثر من </strong><strong>1 </strong><strong>من بين كل </strong><strong>10&nbsp;</strong><strong>أشخاص</strong><strong>):</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدَّم الحمراء مما قد يُسبب شعورًا بالتَّعب وضيقًا بالتنفس (فقر الدَّم [أنيميا]).&nbsp; قد تحتاج إلى الخضوع لعملية نقل دم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد نوع خاص من خلايا الدَّم البيضاء (قلة خلايا المحببات وقلة خلايا العَدِلات).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان (الشعور بالإعياء).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء (الإعياء).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر.</p><p dir="RTL">&nbsp;</p><p><strong>شائعة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10 أشخاص):</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الصفائح الدَّموية - مما قد يُسبب نزيفًا أو كدمات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد كريات الدَّم البيضاء (الخلايا المحببة).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب، وضعف ونقص الطاقة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبة قلبية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق بالتَّنفس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إِسْهال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الفم والشفتين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمّى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هبوط (فشل) القلب الاحتقاني (حالة شديدة لا يستطيع القلب فيها ضخ قدر كافٍ من الدَّم).</p><p><strong>غير شائعة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل ١٠٠ شخص)</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض نشاط النخاع العظمي. من الممكن أن يزداد كبت النخاع العظمي لديك أو يظل مكبوتًا لفترة أطول إذا خضعت للعلاج الكيميائي أو العلاج الإشعاعي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إنتاج غير كاف لخلايا الدَّم في النخاع العظمي (فشل النخاع العظمي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدد غير طبيعي من خلايا الدَّم البيضاء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية شديدة (تفاعل تَأَقِيّ بما في ذلك صدمة تأقية) - قد تصاب فجأة بطفح جلدي مصحوب بحكة (شرى أو أرتكاريا)، تورم اليدين، القدمين، الكاحلين، الوجه، الشفتين، الفم أو الحلق (مما قد يُسبب صعوبة في البلع أو التنفس)، وقد تشعر بأنك ستصاب بالإغماء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى المسالك الهوائية بالجهاز التنفسي العلوي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى المسالك البولية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسمم دموي (تعفن الدَّم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى ناجمة عن الميكروبات التي ليس من طبيعتها التَّسبب في إصابة الجهاز المناعي السليم بالأمراض (عدوى انتهازية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان خلايا الدَّم البيضاء (سرطان الدَّم النخاعي الحاد).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب في النخاع العظمي مما يتسبب في تكوُّن خلايا دم غير طبيعية مما يُؤدي إلى الإصابة بسرطان الدَّم (متلازمة خلل التَّنسج النخاعي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيُّرات في الوزن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الاستقلاب (متلازمة انحلال الورم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك/ التباس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بوخز.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام ضربات القلب أو بطء ضربات القلب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رسم قلب (مُخَطط كهربية القلب) غير طبيعي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض كمية الدَّم التي يمكن للبطين الأيسر ضخها، دون أعراض.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكدُّم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف غزير.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدَّم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالبطن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف بالمعدة أو الأمعاء، وقد يشمل ذلك وجود دم في القيء، حدوث نزيف عند إفراغ الأمعاء أو إخراج براز أسود قطراني.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأغشية المخاطية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات بالكبد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجلد (احمرار).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات بالأظافر (على سبيل المثال: انفصال الظفر من فِراش الظُّفُر، حدوث تغيرات في نسيج الظفر وبنيته).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث تغير في لون بياض العينين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير لون الجلد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسرب السائل إلى ما حوله من أنسجة (تسرب خارج الوريد): o احمرار.</p><p dir="RTL">o&nbsp; تورم.</p><p dir="RTL">o&nbsp; ألم.</p><p dir="RTL">o&nbsp; شعور بالحرقة و/ أو تغير لون الجلد.</p><p dir="RTL">o&nbsp; موت خلايا الأنسجة مما قد يُؤدي إلى الحاجة إلى إزالة الخلايا الميتة والخضوع لعملية زرع الجلد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج غير طبيعية لاختبارات الدَّم لفحص وظائف الكبد والكُلى (ارتفاع مستويات ناقِلَة الأَمينِ الأسبارتية، ارتفاع تركيز الكرياتينين ونتروجين اليوريا بالدَّم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف بالكُلى، ينجم عنه تورم وضعف (اعتلال الكُلى).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير لون البول.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم (وذمة).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات التَّذوق.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انقطاع غير طبيعي للحيض (الطمث).</p><p dir="RTL">&nbsp;</p><p><strong>نادرة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل ١٠٠٠ شخص):</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضرر عضلة القلب مما يمنعها من الضخ كما ينبغي (اعتلال عضلة القلب).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الرئة (الالتهاب الرئوي).</p><p dir="RTL">&nbsp;</p><p><strong>للمرضى الذين يتم علاجهم من التصلب المتعدد: شائعة جدًّا (قد تُؤثر في أكثر من شخص واحد من كل 10 أشخاص)</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى، بما في ذلك عدوى المسالك الهوائية بالجهاز التَّنفسي العلوي والجهاز البولي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان (الشعور بالإعياء).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انقطاع غير طبيعي للحيض (الطمث).</p><p dir="RTL">&nbsp;</p><p><strong>شائعة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10&nbsp;أشخاص)</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدَّم الحمراء مما قد يُسبب شعورًا بالتَّعب وضيقًا بالتنفس (فقر الدَّم [أنيميا]). قد تحتاج إلى الخضوع لعملية نقل دم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد نوع خاص من خلايا الدَّم البيضاء (خلايا المحببات وخلايا الدَّم البيضاء).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء (الإعياء).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إِسْهال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الفم والشفتين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدد غير طبيعي من خلايا الدَّم البيضاء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام ضربات القلب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رسم قلب (مُخَطط كهربية القلب) غير طبيعي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض كمية الدَّم التي يمكن للبطين الأيسر ضخها، دون أعراض.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج غير طبيعية لاختبارات الدَّم لفحص وظائف الكبد (ارتفاع مستويات ناقِلَة الأَمينِ الأسبارتية).</p><p dir="RTL">&nbsp;</p><p><strong>غير شائعة (قد تؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص)</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الرئة (الالتهاب الرئوي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسمم دموي (تعفن الدَّم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى ناجمة عن الميكروبات التي ليس من طبيعتها التَّسبب في إصابة الجهاز المناعي السليم بالأمراض (عدوى انتهازية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان خلايا الدَّم البيضاء (سرطان الدَّم النخاعي الحاد).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب في النخاع العظمي مما يتسبب في تكوُّن خلايا دم غير طبيعية مما يُؤدي إلى الإصابة بسرطان الدَّم (متلازمة خلل التَّنسج النخاعي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إنتاج غير كافٍ لخلايا الدَّم في النخاع العظمي (فشل النخاع العظمي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض نشاط النخاع العظمي. من الممكن أن يزداد كبت النخاع العظمي لديك أو يظل مكبوتًا لفترة أطول إذا خضعت للعلاج الكيميائي أو العلاج الإشعاعي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الصفائح الدَّموية - مما قد يُسبب نزيفًا أو كدمات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد كريات الدَّم البيضاء (خلايا العدلات).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية شديدة (تفاعل تَأَقِيّ بما في ذلك صدمة تأقية) - قد تصاب فجأة بطفح جلدي مصحوب بحكة (شرى أو أرتكاريا)، تورم اليدين، القدمين، الكاحلين، الوجه، الشفتين، الفم أو الحلق (مما قد يسبب صعوبة في البلع أو التنفس)، وقد تشعر بأنك ستصاب بالإغماء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيُّرات في الوزن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك/ التباس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بوخز.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب، وشعور بالضعف ونقص الطاقة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة شديدة لا يستطيع القلب فيها ضخ قدر كاف من الدَّم (هبوط [فشل] القلب الاحتقاني).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضرر عضلة القلب مما يمنعها من الضخ كما ينبغي (اعتلال عضلة القلب).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بطء معدل ضربات القلب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبة قلبية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بكدمات غير معتادة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف غزير.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدَّم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق بالتَّنفس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالبطن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف بالمعدة أو الأمعاء، وقد يشمل ذلك وجود دم في القيء، حدوث نزيف عند إفراغ الأمعاء أو إخراج براز أسود قطراني.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأغشية المخاطية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات بالكبد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات بالأظافر (على سبيل المثال: انفصال الظفر من فِراش الظُّفُر، حدوث تغيرات في نسيج الظفر وبنيته).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث تغير في لون بياض العينين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير لون الجلد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسرب السائل إلى ما حوله من أنسجة (تسرب خارج الوريد):</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالحرقة و/ أو تغير لون الجلد.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; موت خلايا الأنسجة مما قد يُؤدي إلى الحاجة إلى إزالة الخلايا الميتة والخضوع لعملية زرع الجلد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج غير طبيعية لاختبارات الدَّم لفحص وظائف الكبد والكُلى (ارتفاع تركيز الكرياتينين ونتروجين اليوريا في الدَّم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف بالكُلى، ينجم عنه تورم وضعف (اعتلال الكُلى).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير لون البول.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم (وذمة).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمّى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الوفاة المفاجئة.</p><p dir="RTL">&nbsp;</p><p><strong>نادرة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 1000 شخص)</strong></p><p dir="RTL">لا يوجد.</p><p dir="RTL">&nbsp;</p><p>الإبلاغ عن الآثار الجانبية</p><p dir="RTL">إذا أُصبت بأية آثار جانبية، فتحدَّث إلى طبيبك أو الصيدلي أو الممرض(ة). يشمل ذلك أية آثار جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة. بإبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول أمان استخدام هذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستعمل هذا الدَّواء بعد انتهاء تاريخ الصلاحية المدون على العبوة بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">َيخزن في درجة حرارة &nbsp;لا تتعدى 25 درجة مئوية. لا تعرضه للتَّجميد.</p><p dir="RTL"><u>عمر التَّخزين</u><u>:</u></p><p dir="RTL">العبوة المغلفة من أجل البيع: عامان (قبل الإعداد). المحاليل المخففة: لما يصل إلى 24 ساعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من الأدوية عن طريق إلقائها في مياه الصرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعد تستخدمها. ستُساعد هذه الإجراءات في الحفاظ على البيئة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي ميتوكسانترون (في هيئة هيدروكلوريد). يحتوي كل مللي لتر على 2 مجم من ميتوكسانترون (في هيئة هيدروكلوريد).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: كلوريد الصوديوم، أسيتات الصوديوم، حَمْض الخليك الثلجي، سلفات الصوديوم، حمض الهيدروكلوريد (لضبط درجة الحموضة)، ماء للحقن.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُعد عقار ميتوكسانترون &quot;إيبيفيه&quot; محلولًا أزرق صافيًا وخاليًا من الجسيمات، وهو متوفر في زجاجات شفافة في عبوة كرتونية. يتم تغليف 1 أو 5 أو 10 زجاجات متطابقة تحتوي على 10 مجم من ميتوكسانترون لكل 5 مللي لتر أو 20 مجم من ميتوكسانترون لكل 10 مللي لتر في صندوق واحد مصنوع من الورق المقوى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أحجام العبوات: 1&Iacute;5 مللي لتر، 5&Iacute;5 مللي لتر، 10&Iacute;5 مللي لتر، 1&Iacute;10 مللي لتر، 5&Iacute;10 مللي لتر، 10&Iacute;10 مللي لتر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>&nbsp; شركة إيبيفيه فارما المحدودة Nfg.KG</p><p dir="RTL">&nbsp;&nbsp;&nbsp; A-4866 أونتراخ، النمسا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            06/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Mitoxantron “Ebewe” 2 mg/ml - concentrate for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1ml concentrate for solution for infusion contains 2 mg mitoxantrone. Each 5 ml vial contains 10 mg mitoxantrone (as hydrochloride).
Each 10 ml vial contains 20 mg mitoxantrone (as hydrochloride).


Excipient(s) with known effect:
This medicinal product contains 0.148 mmol/ml sodium (3.42mg/ml). Each 5 ml vial contains 0.739 mmol sodium (17.10mg).
Each 10 ml vial contains 1.478 mmol sodium (34.14mg). For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion. 
Clear, blue solution, free of particles.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Mitoxantrone is indicated in the treatment of metastatic breast cancer.</u></p><p>&nbsp;</p><p><u>Mitoxantrone is indicated in the treatment of non-Hodgkin&rsquo;s lymphoma.</u></p><p>&nbsp;</p><p><u>Mitoxantrone is indicated for the treatment of acute myeloid leukaemia (AML) in adults.</u></p><p>&nbsp;</p><p><u>Mitoxantrone in combination regimens is indicated in the remission-induction treatment of blast crisis in chronic myeloid leukaemia.</u></p><p>&nbsp;</p><p><u>Mitoxantrone is indicated in combination with corticosteroids for palliation (e.g. pain relief) related to advanced castrate resistant prostate cancer.</u></p><p>&nbsp;</p><p><u>Mitoxantrone is indicated for treatment of patients with highly active relapsing multiple sclerosis associated with rapidly evolving disability where no alternative therapeutic options exist (see sections 4.2, 4.4 and 5.1).</u></p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Mitoxantrone should be administered under the supervision of a physician experienced in the use of cytotoxic chemotherapy agents.</p><p>&nbsp;</p><p><em>Metastatic Breast Cancer, Non-Hodgkin&rsquo;s Lymphoma: Single Agent Therapy</em>:</p><p>The recommended initial dosage of mitoxantrone used as a single agent is 14 mg/m2 of body surface area, given as a single intravenous dose, which may be repeated at 21-day intervals. A lower&nbsp; initial&nbsp; dosage&nbsp; (12&nbsp; mg/m2&nbsp; or&nbsp; less)&nbsp; is&nbsp; recommended&nbsp; in&nbsp; patients&nbsp; with&nbsp; inadequate bone</p><p>marrow reserves e.g. due to prior chemotherapy or poor general condition.</p><p>&nbsp;</p><p>Dosage modification and the timing of subsequent dosing should be determined by clinical judgement depending on the degree and duration of myelosuppression. For subsequent courses, the prior dose can usually be repeated if white blood cell and platelet counts have returned to normal levels after 21 days. The following table is suggested as a guide to dosage adjustment,&nbsp; in the treatment of advanced breast cancer and non-Hodgkin&rsquo;s lymphoma according to haematological nadir (which usually occurs about 10 days after dosing).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>WBC and platelet nadir</p></td><td style="vertical-align:top"><p>Time to recovery</p></td><td style="vertical-align:top"><p>Subsequent dosing</p></td></tr><tr><td style="vertical-align:top"><p>If WBC nadir &gt; 1,500 &mu;l and platelet nadir &gt; 50,000 &mu;l</p></td><td style="vertical-align:top"><p><u>Recovery &lt; </u>21 days</p></td><td style="vertical-align:top"><p>Repeat prior dose</p></td></tr><tr><td style="vertical-align:top"><p>If WBC nadir &gt; 1,500 &mu;l and platelet nadir &gt; 50,000 &mu;l</p></td><td style="vertical-align:top"><p>Recovery &gt; 21 days</p></td><td style="vertical-align:top"><p>Withhold until recovery then repeat prior dose.</p></td></tr><tr><td style="vertical-align:top"><p>If WBC nadir &lt; 1,500 &mu;l or platelet nadir &lt; 50,000 &mu;l</p></td><td style="vertical-align:top"><p>Any duration</p></td><td style="vertical-align:top"><p>Decrease by 2 mg/m2&nbsp; from</p><p>prior dose after recovery</p></td></tr><tr><td style="vertical-align:top"><p>If WBC nadir &lt; 1,000 &mu;l or platelet nadir &lt; 25,000 &mu;l</p></td><td style="vertical-align:top"><p>Any duration</p></td><td style="vertical-align:top"><p>Decrease&nbsp; by&nbsp; 4&nbsp; mg/m2&nbsp;&nbsp;&nbsp;&nbsp; from</p><p>prior dose after recovery.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Combination Therapy</em></p><p>Mitoxantrone has been given as part of combination therapy. In metastatic breast cancer, combinations of mitoxantrone with other cytotoxic agents including cyclophosphamide and 5- fluorouracil or methotrexate and mitomycin C have been shown to be effective.</p><p>Mitoxantrone has also been used in various combinations for non-Hodgkin&rsquo;s lymphoma; however, data are presently limited and specific regimens cannot be recommended.</p><p>&nbsp;</p><p>In combination regimens mitoxantrone, in starting doses ranging from 7 to 8 to 10 to 12 mg/m2, dependent on the combination and frequency used, has shown effectiveness.</p><p>&nbsp;</p><p>As a guide, when mitoxantrone is used in combination chemotherapy with another myelosuppressive agent, the initial dose of mitoxantrone should be reduced by 2-4 mg/m2 below the doses recommended for single agent usage; subsequent dosing, as outlined in the table</p><p>&nbsp;</p><p>above, depends on the degree and duration of myelosuppression.</p><p>&nbsp;</p><p><em>Acute myeloid leukaemia</em></p><p><em>&nbsp;</em></p><p>Single Agent Therapy in Relapse</p><p>The recommended dosage for remission induction is 12 mg/m2 of body surface area, given as a single intravenous dose daily for five consecutive days (total of 60 mg/m2). In clinical studies with a dosage of 12 mg/m2 daily for 5 days, patients who achieved a complete remission did so as a result of the first induction course.</p><p>&nbsp;</p><p>Combination therapy</p><p>For induction, the recommended dosage is 12 mg/m2&nbsp; of mitoxantrone daily on Days 1 to 3 given as an intravenous infusion, and 100 mg/m2 of cytarabine for 7 days given as a continuous 24-hour infusion on Days 1 to 7.</p><p>&nbsp;</p><p>Most complete remissions will occur following the initial course of induction therapy. In the event of an incomplete antileukaemic response, a second induction course may be given with mitoxantrone given for 2 days and cytarabine for 5 days, using the same daily dosage levels. If severe or life-threatening non- haematological toxicity is observed during the first induction course, the second induction course should be withheld until toxicity resolves.</p><p>&nbsp;</p><p>Consolidation therapy, which was used in two large randomised multicentre trials, consists of mitoxantrone 12 mg/m2 given by intravenous infusion daily on Days 1 and 2, and cytarabine, 100 mg/m2 for 5 days given as a continuous 24-hour infusion on Days 1 to 5. The first course was given approximately 6 weeks after the final induction course; the second was generally administered 4 weeks after the first.</p><p>&nbsp;</p><p>A single course of mitoxantrone 6 mg/m2 intravenous (IV) bolus, etoposide 80 mg/m2 intravenous for a period of 1 hour, and cytarabine (Ara-C) 1 g/m2 intravenous for a period of 6 hours daily for 6 days (MEC) showed antileukaemic activity as salvage therapy for refractory AML.</p><p>&nbsp;</p><p><em>Treatment of blast crisis in (chronic) myeloid leukaemia</em></p><p>Single dose therapy in relapse</p><p>The recommended dosage in relapse is 10 to 12 mg/m2 body surface area given as a single intravenous dose daily over 5 consecutive days (total of 50 to 60 mg/m2).</p><p>&nbsp;</p><p><em>Advanced castrate-resistant prostate cancer </em>Based on data from two comparative trials of mitoxantrone plus corticosteroids versus corticosteroids alone, the recommended dosage of mitoxantrone is 12 to 14 mg/m2 given as a short intravenous infusion every 21 days, in combination with low oral doses of corticosteroids.</p><p>&nbsp;</p><p>Cancer patients who received cumulative doses of 140 mg/m2 either alone or in combination with other chemotherapeutic agents had a cumulative 2.6% probability of clinical congestive heart failure. For this reason, patients should be monitored for evidence of cardiac toxicity and questioned about symptoms of heart failure prior to the initiation of and during treatment.</p><p><em>Multiple Sclerosis</em></p><p>The treatment with mitoxantrone should be administered under the supervision of a physician experienced in the use of cytotoxic chemotherapeutic agents for the treatment of multiple sclerosis.</p><p>&nbsp;</p><p>This treatment should be used only after assessment of the benefit-risk, particularly concerning the haematological and cardiac risks (see section 4.4).</p><p>The treatment must not be initiated in patients who have been previously treated with mitoxantrone.</p><p>The recommended dosage of mitoxantrone is usually 12 mg/m2 body surface area given as a short (approximately 5 to 15 minutes) intravenous infusion that may be repeated every 1-3 months. The maximum lifetime cumulative dose should not exceed 72 mg/m2 (see section 5.1).</p><p>If mitoxantrone is administered repeatedly dosing adjustments should be guided by extent and duration of bone marrow suppression.</p><p>Differential blood count within 21 days after mitoxantrone infusion</p><p>Signs and symptoms of infection and differential blood count with WHO grade 3: following dose 10 mg/m&sup2;</p><p>Signs and symptoms of infection and differential blood count with WHO grade 4: following dose 8 mg/m&sup2;</p><p>Differential blood count 7 days before mitoxantrone infusion</p><p>Signs and symptoms of infection and differential blood count with WHO grade 1: following dose 9 mg/m&sup2;</p><p>Signs and symptoms of infection and differential blood count with WHO grade 2: following dose 6 mg/m&sup2;</p><p>Signs and symptoms of infection and differential blood count with WHO grade 3 to 4: discontinuation of therapy</p><p>In case of non-haematological toxicities WHO grade 2 to 3 the following dose should be adjusted to 10 mg/m&sup2;, in case of non-haematological toxicity grade 4 the treatment should be discontinued.</p><p>&nbsp;</p><p><em><u>Special populations </u>Elderly</em></p><p>In general, dose selection for an elderly patient should be initiated at the low end of the dosing range, reflecting the greater frequency of decreasing hepatic, renal, or cardiac function, and of concomitant disease or treatment with other medicinal products.</p><p><em>Renal Impairment</em></p><p>The safety of mitoxantrone in patients with renal impairment is not established. Mitoxantrone should be used with caution.</p><p><em>Hepatic Impairment</em></p><p>The safety of mitoxantrone in patients with hepatic insufficiency is not established. For patients with hepatic impairment dose adjustment may be necessary as mitoxantrone clearance is reduced by hepatic impairment. There are insufficient data that allows for dose adjustment recommendations. Laboratory measurement cannot predict clearance of the active substance and dose adjustments (see section 5.2).</p><p>&nbsp;</p><p><em>Paediatric Population</em></p><p>Safety and efficacy in paediatric patients have not been established. There is no relevant use of mitoxantrone in the paediatric population.</p><p>&nbsp;</p><p><u>Method of administration </u>For intravenous use only.</p><p>&nbsp;</p><p>Mitoxantron &ldquo;EBEWE&rdquo; should be slowly injected into a free flowing intravenous infusion of isotonic saline or 5% glucose solution over a period of not less than 3 to 5 minutes. The tubing should be inserted preferably into a large vein. If possible, avoid veins over joints or in extremities with compromised venous or lymphatic drainage.</p><p>Mitoxantron &ldquo;EBEWE&rdquo; also can be administered as a short infusion (15 to 30 minutes) diluted in 50 to 100 ml isotonic saline or 5% glucose solution.</p><p>Mitoxantron &ldquo;EBEWE&rdquo; must not be given subcutaneously, intramuscularly, or intra-arterially. Severe local tissue damage may occur if there is extravasation during administration. The medicinal product must also not be given by intrathecal injection.</p><p>If any signs or symptoms of extravasation have occurred, including burning, pain, pruritus, erythema, swelling, blue discolouration, or ulceration, the administration should be stopped immediately (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substanceor to any of the excipients listed in section 6.1, including sulphites that may be produced during the manufacturing of mitoxantrone.
•	Mitoxantrone is contraindicated in women who are breast-feeding (see sections 4.4 and 4.6).

Mitoxantrone must not be used in treatment of multiple sclerosis in pregnant women (see sections 4.4 and 4.6).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Precautions to be taken before handling or administering the medicinal product</u></p><p>Mitoxantrone should be given slowly into a freely flowing intravenous infusion. Mitoxantrone must not be given subcutaneously, intramuscularly, or intra-arterially. There have been reports of local/regional neuropathy, some irreversible, following intra-arterial injection. Severe local tissue damage may occur if there is extravasation during administration. To date, only isolated cases of severe local reactions (necroses) have been described due to extravasation.</p><p>&nbsp;</p><p>Mitoxantron &ldquo;Ebewe&rdquo; must not be given by intrathecal injection. Severe injury with permanent sequelae can result from intrathecal administration. There have been reports of neuropathy and neurotoxicity, both central and peripheral, following intrathecal injection. These reports have included seizures leading to coma and severe neurologic sequelae, and paralysis with bowel and bladder dysfunction.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Cardiac function</em></p><p>Myocardial toxicity, manifested in its most severe form by potentially irreversible and fatal congestive heart failure (CHF), may occur either during therapy with mitoxantrone or months to</p><p>&nbsp;</p><p>years after termination of therapy. This risk increases with cumulative dose. Cancer patients who received cumulative doses of 140 mg/m2 either alone or in combination with other chemotherapeutic agents had a cumulative 2.6% probability of clinical congestive heart failure. In comparative oncology trials, the overall cumulative probability rate of moderate or severe decreases in LVEF at this dose was 13%.</p><p>&nbsp;</p><p>Active or dormant cardiovascular disease, prior or concomitant radiotherapy to the mediastinal/pericardial area, previous therapy with other anthracyclines or anthracenediones, or concomitant use of other cardiotoxic medicinal products may increase the risk of cardiac toxicity. Evaluation of the left-ventricular ejection fraction (LVEF) by echocardiogram or multiple-gated acquisition (MUGA) is recommended prior to administration of the initial dose of mitoxantrone in cancer patients. Cardiac function for cancer patients should be carefully monitored during treatment. LVEF evaluation is recommended at regular intervals and/or if signs or symptoms of congestive heart failure develop. Cardiotoxicity can occur at any time during mitoxantrone therapy, and the risk increases with cumulative dose. Cardiac toxicity with mitoxantrone may occur at lower cumulative doses whether or not cardiac risk factors are present.</p><p>&nbsp;</p><p>Because of the possible danger of cardiac effects in patients previously treated with daunorubicin or doxorubicin, the benefit-to-risk ratio of mitoxantrone therapy in such patients should be determined before starting therapy.</p><p>&nbsp;</p><p>Acute congestive heart failure may occasionally occur in patients treated with mitoxantrone for acute myeloid leukaemia.</p><p>This also has been reported for MS patients treated with mitoxantrone. Functional cardiac changes may occur in patients with multiple sclerosis treated with mitoxantrone. Evaluation of the left-ventricular ejection fraction (LVEF) by echocardiogram or MUGA is recommended prior to administration of the initial dose of mitoxantrone and prior to each dose in multiple sclerosis patients and yearly for up to 5 years after the end of therapy. Cardiotoxicity can occur at any time during mitoxantrone therapy, and the risk increases with cumulative dose. Cardiac toxicity with mitoxantrone may occur at lower cumulative doses whether or not cardiac risk factors are present. Ordinarily, patients with multiple sclerosis should not receive a lifetime cumulative dose greater than 72 mg/m2. Mitoxantrone should not ordinarily be administered to multiple sclerosis patients, with either LVEF of &lt; 50% or a clinically-significant reduction in LVEF.</p><p>&nbsp;</p><p><em>Bone marrow suppression</em></p><p>Therapy with mitoxantrone should be accompanied by close and frequent monitoring of haematological and chemical laboratory parameters, as well as frequent patient observation. A complete blood count, including platelets, should be obtained prior to administration of the initial dose of mitoxantrone, 10 days following the administration and prior to each subsequent infusion and in the event that signs and symptoms of infection develop. Patients should be informed about risks, symptoms and signs of acute leukaemia and prompted to seek medical attendance if any such symptoms should occur even after the five year period has passed.</p><p>&nbsp;</p><p>Myelosuppression may be more severe and prolonged in patients with poor general condition, or prior chemotherapy and/or radiotherapy.</p><p>&nbsp;</p><p>Except for the treatment of acute myeloid leukaemia, mitoxantrone therapy generally should not</p><p>3</p><p>be given to patients with baseline neutrophil counts of less than 1,500 cells/mm . It is</p><p>recommended that frequent peripheral blood cell counts are performed on all patients receiving</p><p>&nbsp;</p><p>mitoxantrone in order to monitor the occurrence of bone marrow suppression, primarily neutropenia, which may be severe and result in infection.</p><p>2</p><p>When mitoxantrone is used in high doses (&gt; 14 mg/m /d x 3 days) such as indicated for the</p><p>treatment of leukaemia, severe myelosuppression will occur.</p><p>&nbsp;</p><p>Particular care should be given to assuring full haematological recovery before undertaking consolidation therapy (if this treatment is used) and patients should be monitored closely during this phase. Mitoxantrone administered at any dose can cause myelosuppression.</p><p>&nbsp;</p><p><em>Secondary acute myeloid leukaemia and myelodysplastic syndrome </em>Topoisomerase II inhibitors, including mitoxantrone hydrochloride, when used as monotherapy or esepcially concomitantly with other antineoplastic agents and/or radiotherapy, have been associated with the development of Acute Myeloid Leukaemia (AML) or Myelodysplastic Syndrome (MDS). Because of the risk of development of secondary malignancies, the benefit-to-risk ratio of mitoxantrone therapy should be determined before starting therapy.</p><p>&nbsp;</p><p><em>Use after other MS-specific treatments</em></p><p>The safety and efficacy of mitoxantrone have not been studied after treatment with natalizumab, fingolimod, alemtuzumab, dimethyl fumarate, or teriflunomide.</p><p><em>Non-metastatic breast cancer</em></p><p>In the absence of sufficient efficacy data in the adjuvant treatment of breast cancer and accounting for the increased risk of leukaemia, mitoxantrone should only be used for metastatic breast cancer.</p><p>&nbsp;</p><p><em>Infections</em></p><p>Patients who receive immunosuppressive agents like mitoxantrone have a reduced immunological response to infection. Systemic infections should be treated concomitantly with or just prior to commencing therapy with mitoxantrone.</p><p>&nbsp;</p><p><em>Vaccination</em></p><p>Immunisation with live virus vaccines (e.g. yellow fever vaccination) increases the risk of infection and other adverse reactions such as vaccinia gangrenosa and generalized vaccinia, in patients with reduced immunocompetence, such as during treatment with mitoxantrone.</p><p>Therefore, live virus vaccines should not be administered during therapy. It is advised to use live virus vaccines with caution after stopping chemotherapy, and vaccinate not sooner than 3 months after the last dose of chemotherapy (see section 4.5).</p><p>&nbsp;</p><p><em>Contraception in males and females</em></p><p>Mitoxantrone is genotoxic and is considered a potential human teratogen. Therefore men under therapy must be advised not to father a child and to use contraceptive measures during and at least 6 months after therapy. Women of childbearing potential should have a negative pregnancy test prior to each dose, and use effective contraception during therapy and for at least 4 months after cessation of therapy.</p><p>&nbsp;</p><p><em>Breast-feeding</em></p><p>Mitoxantrone has been detected in breast-milk for up to one month after the last administration. Because of the potential for serious adverse reactions in infants from mitoxantrone, breast- feeding is contraindicated (see section 4.3) and must be discontinued before starting treatment.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Fertility</em></p><p>&nbsp;</p><p>Women of childbearing potential should be informed about increased risk of transitory or persistent amenorrhoea (see section 4.6).</p><p>&nbsp;</p><p><em>Mutagenicity and carcinogenicity</em></p><p>Mitoxantrone was found to be mutagenic in bacterial and mammalian test systems, as well as in vivo in rats. The active substance was carcinogenic in experimental animals at doses below the proposed clinical dose. Therefore, mitoxantrone has the potential to be carcinogenic in humans.</p><p>&nbsp;</p><p><em>Tumour lysis syndrome</em></p><p>Cases of tumour lysis syndrome were reported with the use of mitoxantrone. Levels of uric acid, electrolytes and urea should be monitored.</p><p><em>Discolouration of urine and other tissues</em></p><p>Mitoxantrone may colour the urine blue-green for up to 24 hours after administration and patients should be advised to expect this during therapy. Bluish discolouration of the sclera, skin and nails may also occur.</p><p>&nbsp;</p><p>The content of sodium per vial: 10mg/5ml: 0.739mmol (17.10mg) sodium</p><p>20mg/10ml: 1.478mmol (34.14mg) sodium.</p><p>&nbsp;</p><p>To be taken with consideration by patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Combining mitoxantrone with potentially cardiotoxic active substances (e.g. anthracyclines) increases the risk of cardiac toxicity.</p><p>Topoisomerase II inhibitors, including mitoxantrone, in combination with other antineoplastic agents and/or radiotherapy, have been associated with the development of acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) (see see section 4.4 and 4.8).</p><p>&nbsp;</p><p>Mitoxantrone causes myelosuppression as an extension of its pharmacological action. Myelosuppresion can be increased when it is used in combination chemotherapy with another myelosuppressive agent such as for treatment of breast cancer.</p><p>&nbsp;</p><p>The combination of mitoxantrone with other immunosuppressive agents may increase the risk of excessive immunodepression and lymphoproliferative syndrome.</p><p>&nbsp;</p><p>Immunisation with live virus vaccines (e.g. yellow fever vaccination) increases the risk of infection and other adverse reactions such as vaccinia gangrenosa and generalized vaccinia, in patients with reduced immunocompetence, such as during treatment with mitoxantrone.</p><p>Therefore, live virus vaccines should not be administered during therapy. It is advised to use live virus vaccines with caution after stopping chemotherapy, and vaccinate not sooner than 3 months after the last dose of chemotherapy (see section 4.4).</p><p>&nbsp;</p><p>The combination of vitamin K antagonists and cytotoxic agents may result in an increased risk of bleeding. In patients receiving oral anticoagulant therapy, the prothrombin time ratio or INR</p><p>&nbsp;</p><p>should be closely monitored with the addition and withdrawal of treatment with mitoxantrone and should be reassessed more frequently during concurrent therapy. Adjustments of the anticoagulant dose may be necessary in order to maintain the desired level of anticoagulation.</p><p>&nbsp;</p><p>Mitoxantrone has been demonstrated to be a substrate for the BCRP transporter protein in vitro. Inhibitors of the BCRP transporter (e.g. eltrombopag, gefitinib) could result in an increased bioavailability. In a pharmacokinetic study in children with de novo acute myeloid leukaemia, ciclosporin co-medication resulted in a 42% decreased clearance of mitoxantrone. Inducers of the BCRP transporter could potentially decrease mitoxantrone exposure.</p><p>&nbsp;</p><p>Mitoxantrone and its metabolites are excreted in bile and urine, but it is not known whether the metabolic or excretory pathways are saturable, may be inhibited or induced, or if mitoxantrone and its metabolites undergo enterohepatic circulation (see section 5.2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Contraception in males and females</u></p><p>Mitoxantrone is genotoxic and is considered a potential human teratogen. Therefore men under therapy must be advised not to father a child and to use contraceptive measures during and at least 6 months after therapy. Women of childbearing potential must be advised to avoid becoming pregnant; should have a negative pregnancy test prior to each dose and use effective contraception during therapy and for at least 4 months after cessation of therapy.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p><strong><em>There are very limited data on the use of mitoxantrone in pregnant women. Mitoxantrone&nbsp; was not teratogenic in animal studies at doses below human exposure, but caused reproductive toxicity (see section 5.3). Mitoxantrone is considered a potential human teratogen because of its mechanism of action and the developmental effects demonstrated by related agents. For this reason, the use of mitoxantrone to treat MS is contraindicated for pregnant women (see section 4.3). When used for treatment in other&nbsp; indications mitoxantrone should not be administered during pregnancy in particular during the first trimester of pregnancy. In each individual case the benefit of treatment must be weighed up against the possible risk to the foetus. If this medicinal product is used during pregnancy or if the patient becomes pregnant while taking mitoxantrone, the patient should be informed of the potential risk to the foetus and genetic counselling should be provided.</em></strong></p><p><u>Breast-feeding</u></p><p>Mitoxantrone is excreted in breast-milk and has been detected in breast-milk for up to one month after the last administration. Because of the potential for serious adverse reactions in infants from mitoxantrone, breast-feeding is contraindicated (see section 4.3) and must be discontinued before starting treatment.</p><p><u>Fertility</u></p><p>Women treated with Mitoxantrone have an increased risk of transitory or&nbsp; persistent amenorrhoea and therefore preservation of gametes should be considered prior to therapy. In men, no data are available, but tubular atrophy of the testes and reduced sperm counts were observed in animals (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mitoxantrone has minor influence on the ability to drive and use machines. Confusion and fatigue may occur following administration of mitoxantrone (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong><u>Summary of the safety profile</u></p><p>The most serious side effects with mitoxantrone are myocardial toxicity and myelosuppression. The most common side effects with mitoxantrone (seen in more than 1 patient in 10) are anaemia, leucopenia, neutropenia, infections, amenorrhoea, alopecia, nausea and vomiting.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>The table below is based on safety data derived from clinical trials and spontaneous reporting in oncological indications and from clinical trials, post authorisation safety&nbsp; studies&nbsp; and spontaneous reporting for patients treated for multiple sclerosis. Frequencies are defined using the following convention:Very common (&sup3;1/10); common (&sup3;1/100 to &lt;1/10); uncommon (&sup3;1/1,000 to &lt;1/100); rare (&sup3;1/10,000 to &pound;1/1,000); very rare (&pound;1/10,000), not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Oncology</strong></p></td><td style="vertical-align:top"><p><strong>Multiple Sclerosis</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Infections and Infestations</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Infection (including fatal outcome)</p></td><td style="vertical-align:top"><p>Infection (including fatal outcome)</p><p>Urinary tract infection</p><p>Upper respiratory tract infection</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Urinary tract infection</p><p>Upper respiratory tract infection Sepsis</p><p>Opportunistic infections</p></td><td style="vertical-align:top"><p>Pneumonia Sepsis</p><p>Opportunistic infections</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Pneumonia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Neoplasms benign and malignant (including cysts and polyps)</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Acute myeloid leukaemia, myelodysplastic syndrome, acute leukaemia</p></td><td style="vertical-align:top"><p>Acute myeloid leukaemia, myelodysplastic syndrome, acute leukaemia</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Blood and lymphatic system disorders</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Anaemia Neutropenia Leukopenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Thrombocytopenia Granulocytopenia</p></td><td style="vertical-align:top"><p>Anaemia Leukopenia Granulocytopenia</p><p>White blood cell count abnormal</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Myelosuppression Bone marrow failure</p><p>White blood cell count abnormal</p></td><td style="vertical-align:top"><p>Bone marrow failure Myelosuppression</p><p>Thrombocytopenia</p><p>&nbsp;</p><p>Neutropenia</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Immune system disorders</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Anaphylaxis/anaphylactoid reactions (including shock)</p></td><td style="vertical-align:top"><p>Anaphylaxis/anaphylactoid reactions (including shock)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Metabolism and nutrition disorders</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Weight fluctuations Tumour lysis syndrome*</p></td><td style="vertical-align:top"><p>Anorexia</p><p>Weight fluctuations</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>* Acute T and B lymphoblastic leukaemia and non-Hodgkin lymphomas (NHL) are most commonly associated with TLS</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Nervous system disorders</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Lethargy</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Anxiety Confusion Headache Paraesthesia</p></td><td style="vertical-align:top"><p>Anxiety Confusion Paraesthesia Lethargy</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Eye disorders</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Scleral discolouration</p></td><td style="vertical-align:top"><p>Scleral discolouration</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Cardiac disorders</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Congestive heart failure</p><p>Myocardial infarction (including fatal events)</p></td><td style="vertical-align:top"><p>Arrhythmia Electrocardiogram abnormal</p><p>Left ventricular ejection fraction decreased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Arrhythmia</p><p>Sinus bradycardia Electrocardiogram abnormal</p><p>Left ventricular ejection fraction decreased</p></td><td style="vertical-align:top"><p>Congestive heart failure Cardiomyopathy</p><p>Sinus bradycardia</p><p>Myocardial infarction (including fatal events)</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Cardiomyopathy</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Vascular disorders</em></strong></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Contusion Haemorrhage Hypotension</p></td><td style="vertical-align:top"><p>Contusion Haemorrhage Hypotension</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Respiratory, thoracic and mediastinal disorders</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dyspnoea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspnoea</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Gastrointestinal disorders</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Nausea Vomiting</p></td><td style="vertical-align:top"><p>Nausea</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Constipation Diarrhoea Stomatitis</p></td><td style="vertical-align:top"><p>Constipation Diarrhoea Stomatitis Vomiting</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Abdominal pain Gastrointestinal haemorrhage Mucosal inflammation Pancreatitis</p></td><td style="vertical-align:top"><p>Abdominal pain Gastrointestinal haemorrhage Mucosal inflammation Pancreatitis</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Hepatobiliary disorders</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Elevated aspartate aminotransferase levels</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hepatotoxicity</p><p>Elevated aspartate aminotransferase levels</p></td><td style="vertical-align:top"><p>Hepatotoxicity</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Skin and subcutaneous tissue disorders</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Alopecia</p></td><td style="vertical-align:top"><p>Alopecia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Erythema Nail disorders Rash</p><p>Skin discolouration</p><p>Tissue necrosis (after extravasation)</p></td><td style="vertical-align:top"><p>Nail disorders Rash</p><p>Skin discolouration</p><p>Tissue necrosis (after extravasation)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Renal and urinary disorders</em></strong></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Elevated serum creatinine</p><p>Elevated blood urea nitrogen levels</p><p>Nephropathy toxic Urine discolouration</p></td><td style="vertical-align:top"><p>Elevated serum creatinine</p><p>Elevated blood urea nitrogen levels</p><p>Nephropathy toxic Urine discolouration</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Reproductive system and breast disorders</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Amenorrhoea*</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Amenorrhoea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>* Amenorrhea may be prolonged and may be consistent with premature menopause</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>General disorders and administration site conditions</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Asthenia</p><p>Fatigue Pyrexia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Oedema Extravasation* Dysgeusia</p></td><td style="vertical-align:top"><p>Asthenia Fatigue Oedema Pyrexia Extravasation* Sudden death**</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>* Extravasation at the infusion site has been reported, which may result in erythema, swelling, pain, burning and/or blue discolouration of the skin. Extravasation can result in tissue necrosis with resultant need for debridement and skin grafting. Phlebitis has also been reported at the site of infusion.</p><p>&nbsp;</p><p>&nbsp;</p><p>** The casual relationship to mitoxantrone administration is uncertain.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>Myocardial toxicity, manifested in its most severe form by potentially irreversible and fatal congestive heart failure (CHF), may occur either during therapy with mitoxantrone or months to years after termination of therapy. This risk increases with cumulative dose. In clinical trials cancer patients who received cumulative doses of 140 mg/m2 either alone or in combination with other chemotherapeutic agents had a cumulative 2.6% probability of clinical congestive heart failure.</p><p>Myelosuppression is a dose-limiting undesirable effect of mitoxantrone. Myelosuppression can be more pronounced and longer-lasting in patients who have previously received chemotherapy or radiotherapy. In a clinical trial with acute leukaemia patients, significant myelosuppression occurred in all patients who were given mitoxantrone therapy. Amongst the 80 enrolled patients the median values for the lowest white blood cell count and platelet count were 400/&mu;l (WHO grade 4), and 9.500/&mu;l (WHO grade 4), respectively. Haematological toxicity is difficult to evaluate in acute leukaemia because traditional parameters of bone marrow depression such as white blood cell and platelet counts are confounded by marrow replacement with leukemic cells.</p><p>&nbsp;</p><p><em><u>Multiple sclerosis population</u></em></p><p><em>&nbsp;</em></p><p><em>Haematological toxicity</em></p><p>A neutropenia can occur after each administration. This is in general a transient neutropenia with the lowest count of leucocytes at day 10 after the infusion and recovered around day 20. A reversible thrombocytopenia can also be observed. Haematological parameters should be regularly monitored (see section 4.4).</p><p>&nbsp;</p><p>Fatal cases of Acute Myeloid Leukaemia (AML) have been reported (see section 4.4).</p><p>&nbsp;</p><p><em>Cardiac toxicity</em></p><p>Cases of ECG anomalies have been reported. Cases of congestive heart failure with left- ventricular ejection fraction (LVEF) &lt; 50 % have also been reported (see section 4.4).</p><p><u>Paediatric population</u></p><p>Treatment with mitoxantrone is not recommended in the paediatric population. Safety and efficacy have not been established.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no known specific antidote for mitoxantrone. Accidental overdoses have been reported. Four patients receiving 140 to 180 mg/m2 as a single bolus injection died as a result of severe leukopenia with infection. Haematological support and antimicrobial therapy may be required during prolonged periods of severe myelosuppression.</p><p>&nbsp;</p><p>Although patients with severe renal failure have not been studied, mitoxantrone is extensively tissue bound and it is unlikely that the therapeutic effect or toxicity would be mitigated by peritoneal or haemodialysis.</p><p>&nbsp;</p><p>Haematopoietic, gastrointestinal, hepatic or renal toxicity may be seen, depending on the dosage given and the physical condition of the patient. In cases of overdosage patients should be monitored closely. Treatment should be symptomatic and supportive.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Anthracyclines and related substances ATC Code: L 01 DB 07</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Mitoxantrone, a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks. Mitoxantrone also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an enzyme responsible for uncoiling and repairing damaged DNA. It has a cytocidal effect on both proliferating and non-</p><p>proliferating cultured human cells, suggesting lack of cell cycle phase specificity and activity against rapidly proliferating and slow-growing neoplasms. Mitoxantrone blocks the cell cycle in G2-phase leading to an increase of cellular RNA and polyploidy.</p><p>&nbsp;</p><p>Mitoxantrone has been shown in vitro to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, tumour necrosis factor alpha, and interleukin-2.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>Mitoxantrone, a synthetic anthracenedione derivative, is an established cytotoxic, antineoplastic agent. Its therapeutic efficacy has been reported in numerous malignancies. Its presumed mechanism of action in MS is immunosuppression.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>Treatment with mitoxantrone 12 to 14 mg/m&sup2; was effective in the treatment of various cancers. This dosage is given in 21 day-cycles, for induction therapy in AML during three consecutive days, for consolidation therapy during two days. Mitoxantrone is active when given alone or in combination with other anticancer agents or corticosteroids.</p><p>&nbsp;</p><p>Mitoxantrone in combination with other cytostatic active substances is effective in the treatment of metastatic breast cancer, also in patients who failed adjuvant therapy with an anthracycline- containing regimen.</p><p>&nbsp;</p><p>Mitoxantrone in combination with corticosteroids improves pain control, and quality of life in patients with advanced castrate resistant prostate cancer, without any improvement in overall survival. Mitoxantrone in combination with cytarabine as initial induction treatment is at least as effective for inducing remission as daunorubicin combinations in adult patients with previously untreated AML. Mitoxantrone alone or in combination with other cytostatic medicinal products shows objective response in patients with several types of NHL. The long-term usefulness of mitoxantrone is limited by emerging cancer resistance which ultimately may result in fatal outcome when used as last-line therapy.</p><p>Treatment with mitoxantrone 12 mg/m&sup2; administered every three months was superior to 5 mg/m&sup2; and placebo in one clinical study with highly active inflammatory active MS disease. A reduction of neurologic disability worsening and frequency of clinical relapses was observed. In the several studies in multiple sclerosis the effective cumulative dose ranged from 36 mg/m to 120 mg/m . Single doses ranged from 5 to 12 mg/m , dose intervals from once per month to once per 3 months. Also the time course over which the cumulative dose was given ranged from 3 to 24 months. However, cardiotoxicity increases with cumulative doses. A cumulative dose of 72 mg/m&sup2; is still effective and associated with less cardiotoxicity than higher cumulative doses. Hence, patients with multiple sclerosis should not receive a lifetime cumulative dose greater than 72 mg/m&sup2;.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Safety and efficacy in paediatric patients have not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>The pharmacokinetics of mitoxantrone in patients following single-dose intravenous administration can be characterised by a three-compartment model. In patients administered 15-90 mg/m , there is a linear relationship between dose and the area under the concentration curve (AUC). Plasma accumulation of active substance was not apparent when mitoxantrone was administered either daily for five days or as a single dose every three weeks.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Distribution to tissues is extensive: steady-state volume of distribution exceeds 1,000 L/m . Plasma concentrations decrease rapidly during the first two hours and slowly thereafter.</p><p>Mitoxantrone is 78% bound to plasma proteins. The fraction bound is independent of concentration and is not affected by the presence of phenytoin, doxorubicin, methotrexate, prednisone, prednisolone, heparin, or aspirin. Mitoxantrone does not cross the blood-brain barrier. Distribution into testes is relatively low.</p><p>&nbsp;</p><p><u>Biotransformation and elimination</u></p><p>The pathways leading to the metabolism of mitoxantrone have not been elucidated. Mitoxantrone is excreted slowly in urine and faeces as either unchanged active substance or as inactive metabolites. In human studies, only 10 % and 18 % of the dose were recovered in urine and faeces respectively as either active substance or metabolite during the 5-day period following administration of the medicinal product. Of the material recovered in urine, 65 % was unchanged active substance. The remaining 35 % was composed of monocarboxylic and dicarboxylic acid derivatives and their glucuronide conjugates.</p><p>&nbsp;</p><p>Many of the reported half-life values for the elimination phase are between 10 and 40 hours, but several other authors have reported much longer values of between 7 and 12 days. Differences in the estimates may be due to the availability of data at late times after doses, weighing of the data and assay sensitivity.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>Mitoxantrone clearance may be reduced by hepatic impairment.</p><p>There does not seem to be relevant differences in pharmacokinetics of mitoxantrone between elderly and young adult patients. The effect of gender, race, and renal impairment on mitoxantrone pharmacokinetics is unknown.</p><p>Mitoxantrone pharmacokinetics in the paediatric population is unknown.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single and repeat toxicity studies were conducted in mouse, rat, dog, rabbits, and monkey. The haematopoietic system was the primary target organ of toxicity showing myelosuppression.</p><p>Heart, kidney, gastrointestinal tract, and testes were additional targets. Tubular atrophy of the testes and decreased sperm counts were observed.</p><p>&nbsp;</p><p>Mitoxantrone was mutagenic and clastogenic in all in vitro test systems and in rats in vivo. Carcinogenic effects were seen in rat and in male mice. Treatment of pregnant rats during the organogenesis period of gestation was associated with foetal growth retardation at doses &gt; 0.01 times the recommended human dose on an mg/m basis. When pregnant rabbits were treated during organogenesis, an increased incidence of premature delivery was observed at doses &gt; 0.01 times the recommended human dose on an mg/m basis. No teratogenic effects were observed in these studies, but the maximum doses tested were well below the recommended human dose (0.02 and 0.05 times in rats and rabbits, respectively, on an mg/m basis). No</p><p>effects were observed on pup development or fertility in the two generation study in rats.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium chloride</p><p>Sodium acetate (E 262)</p><p>Acetic acid glacial (E 260)</p><p>Sodium sulphate (E 514)</p><p>Hydrochloric acid (for pH adjustment)</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>Mitoxantrone should not be mixed with heparin in the same infusion since a precipitate may form. Mitoxantrone should not be mixed with other medicinal product in the same infusion.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Packaged for sale: 2 years (before reconstitution). 
Diluted solutions: up to 24 hours.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;Store below 25&deg;C.</p><p>&nbsp;</p><p>Chemical and physical in-use stability has been demonstrated for 24 hours at room temperature. From a microbiological point of view, the diluted medicinal product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours, unless dilution has taken place in controlled and validated aseptic conditions. See section 6.6 Instruction for use and handling and disposal.</p><p>&nbsp;</p><p>Do not refrigerate or freeze.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Colourless glass vials (Type I) with a fluoropolymer-coated halobutyl rubber stopper with aluminium crimp cap. 1, 5 or 10 vials are packed in a carton.</p><p>&nbsp;</p><p>Pack sizes: 1x5 ml, 5x5 ml, 10x5 ml, 1x10 ml, 5x10 ml and 10x10 ml.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements for cytotoxic agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Ebewe Pharma Ges.m.b.H. Nfg.KG
 A-4866 Unterach, AUSTRIA


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                06/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>